{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T22:24:51Z","timestamp":1793744691736,"version":"4.6.1"},"reference-count":304,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:00:00Z","timestamp":1786406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000049","name":"U.S. Department of Health & Human Services | NIH | National Institute on Aging","doi-asserted-by":"publisher","award":["RF1AG084635"],"award-info":[{"award-number":["RF1AG084635"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02873-4","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:02:10Z","timestamp":1786406530000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CAR T cell therapy beyond cancer: current status, challenges and future prospects"],"prefix":"10.1038","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9394-7321","authenticated-orcid":false,"given":"Saurabh","family":"Upadhyay","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sungwoo","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirti","family":"Upmanyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9074-3331","authenticated-orcid":false,"given":"Moustafa T.","family":"Gabr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,11]]},"reference":[{"key":"2873_CR1","doi-asserted-by":"crossref","unstructured":"Blum, P. & Kayser, S. Chimeric Antigen Receptor (CAR) T-cell therapy in hematologic malignancies: clinical implications and limitations. Cancers 16, 1599 (2024).","DOI":"10.3390\/cancers16081599"},{"key":"2873_CR2","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1038\/s41423-024-01207-0","volume":"21","author":"L Peng","year":"2024","unstructured":"Peng, L. et al. CAR-T and CAR-NK as cellular cancer immunotherapy for solid tumors. Cell Mol. Immunol. 21, 1089\u20131108 (2024).","journal-title":"Cell Mol. Immunol."},{"key":"2873_CR3","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/S2352-3026(19)30115-2","volume":"6","author":"Z Yan","year":"2019","unstructured":"Yan, Z. et al. A combination of humanised anti-CD19 and anti-BCMA CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, phase 2 trial. Lancet Haematol. 6, e521\u2013e529 (2019).","journal-title":"Lancet Haematol."},{"key":"2873_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13045-025-01769-0","volume":"19","author":"X Chen","year":"2025","unstructured":"Chen, X. et al. Challenges and strategies in clinical applications of CAR-T therapy for autoimmune diseases. J. Hematol. Oncol. 19, 1 (2025).","journal-title":"J. Hematol. Oncol."},{"key":"2873_CR5","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1016\/j.amjmed.2025.03.024","volume":"138","author":"EJ Goetzl","year":"2025","unstructured":"Goetzl, E. J. Expanding therapeutic strategies for chimeric antigen receptor T cells. Am. J. Med. 138, 1128\u20131131 (2025).","journal-title":"Am. J. Med."},{"key":"2873_CR6","doi-asserted-by":"crossref","unstructured":"Lundstrom, K. Viral vectors in gene therapy: Where do we stand in 2023? Viruses. 15, 698 (2023).","DOI":"10.3390\/v15030698"},{"key":"2873_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41586-020-2403-9","volume":"583","author":"C Amor","year":"2020","unstructured":"Amor, C. et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature 583, 127\u2013132 (2020).","journal-title":"Nature"},{"key":"2873_CR8","doi-asserted-by":"publisher","first-page":"122556","DOI":"10.1016\/j.lfs.2024.122556","volume":"344","author":"Z Yang","year":"2024","unstructured":"Yang, Z., Liu, Y. & Zhao, H. CAR T treatment beyond cancer: hope for immunomodulatory therapy of non-cancerous diseases. Life Sci. 344, 122556 (2024).","journal-title":"Life Sci."},{"key":"2873_CR9","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1056\/NEJMoa2313812","volume":"390","author":"Y Hu","year":"2024","unstructured":"Hu, Y. et al. Sequential CD7 CAR T-cell therapy and allogeneic HSCT without GVHD prophylaxis. N. Engl. J. Med. 390, 1467\u20131480 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR10","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/j.cels.2022.09.006","volume":"13","author":"S Lee","year":"2022","unstructured":"Lee, S., Khalil, A. S. & Wong, W. W. Recent progress of gene circuit designs in immune cell therapies. Cell Syst. 13, 864\u2013873 (2022).","journal-title":"Cell Syst."},{"key":"2873_CR11","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","volume":"10","author":"GJ Kembuan","year":"2024","unstructured":"Kembuan, G. J., Kim, J. Y., Maus, M. V. & Jan, M. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends Cancer 10, 312\u2013331 (2024).","journal-title":"Trends Cancer"},{"key":"2873_CR12","doi-asserted-by":"publisher","first-page":"2165368","DOI":"10.1080\/19382014.2023.2165368","volume":"15","author":"S Sithara","year":"2023","unstructured":"Sithara, S., Crowley, T., Walder, K. & Aston-Mourney, K. Identification of reversible and druggable pathways to improve beta-cell function and survival in Type 2 diabetes. Islets 15, 2165368 (2023).","journal-title":"Islets"},{"key":"2873_CR13","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.cell.2009.06.036","volume":"138","author":"HW Virgin","year":"2009","unstructured":"Virgin, H. W., Wherry, E. J. & Ahmed, R. Redefining chronic viral infection. Cell 138, 30\u201350 (2009).","journal-title":"Cell"},{"key":"2873_CR14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2110025118","volume":"118","author":"DS Foster","year":"2021","unstructured":"Foster, D. S. et al. Integrated spatial multiomics reveals fibroblast fate during tissue repair. Proc. Natl. Acad. Sci. USA 118, e2110025118 (2021).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2873_CR15","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.tcb.2024.06.007","volume":"35","author":"T-W Wang","year":"2025","unstructured":"Wang, T.-W. & Nakanishi, M. Immune surveillance of senescence: potential application to age-related diseases. Trends Cell Biol. 35, 248\u2013257 (2025).","journal-title":"Trends Cell Biol."},{"key":"2873_CR16","first-page":"566","volume":"73","author":"E Hildt","year":"2024","unstructured":"Hildt, E. & Hu, J. New facet of CARs: HBV-specific CARs as inhibitors of virus morphogenesis and release. Gut 73, 566\u2013567 (2024).","journal-title":"Gut"},{"key":"2873_CR17","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41420-024-01976-7","volume":"10","author":"Y Deng","year":"2024","unstructured":"Deng, Y. et al. Targeting senescent cells with NKG2D-CAR T cells. Cell Death Discov. 10, 217 (2024).","journal-title":"Cell Death Discov."},{"key":"2873_CR18","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","volume":"60","author":"A Rampotas","year":"2025","unstructured":"Rampotas, A., Richter, J., Isenberg, D. & Roddie, C. CAR-T cell therapy embarks on autoimmune disease. Bone Marrow Transpl. 60, 6\u20139 (2025).","journal-title":"Bone Marrow Transpl."},{"key":"2873_CR19","doi-asserted-by":"publisher","first-page":"106812","DOI":"10.1016\/j.msard.2025.106812","volume":"104","author":"D Ortu\u00f1o-Sahag\u00fan","year":"2025","unstructured":"Ortu\u00f1o-Sahag\u00fan, D., Hermosillo-Abundis, C., Reyes-Mata, M. P. & Arias Carri\u00f3n, \u00d3 CAR T cells for multiple sclerosis: engineering T cells to disrupt chronic B cell\u2013driven neuroinflammation. Mult. Scler. Relat. Disord. 104, 106812 (2025).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"2873_CR20","doi-asserted-by":"publisher","first-page":"1634090","DOI":"10.3389\/fimmu.2025.1634090","volume":"16","author":"F Gaspal","year":"2025","unstructured":"Gaspal, F. et al. \u2018Immune reset plus\u2019: the case for combining immunotherapies to maintain self-tolerance in autoimmune diseases. Front. Immunol. 16, 1634090 (2025).","journal-title":"Front. Immunol."},{"key":"2873_CR21","doi-asserted-by":"crossref","unstructured":"M\u00fcller, M., Pavlovic, I., Wiberg, A. & Burman, J. Longitudinal immune profiling following autologous hematopoietic stem cell transplantation in multiple sclerosis: insights into immune reconstitution and disease modulation. Front. Immunol. 16, 1601223 (2025).","DOI":"10.3389\/fimmu.2025.1601223"},{"key":"2873_CR22","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","volume":"6","author":"K Shah","year":"2021","unstructured":"Shah, K., Al-Haidari, A., Sun, J. & Kazi, J. U. T cell receptor (TCR) signaling in health and disease. Signal. Transduct. Target Ther. 6, 412 (2021).","journal-title":"Signal. Transduct. Target Ther."},{"key":"2873_CR23","doi-asserted-by":"publisher","first-page":"1615212","DOI":"10.3389\/fimmu.2025.1615212","volume":"16","author":"AA Alsaieedi","year":"2025","unstructured":"Alsaieedi, A. A. & Zaher, K. A. Tracing the development of CAR-T cell design: from concept to next-generation platforms. Front Immunol. 16, 1615212 (2025).","journal-title":"Front Immunol."},{"key":"2873_CR24","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adj6251","volume":"10","author":"L Lu","year":"2024","unstructured":"Lu, L. et al. Enhancing the safety of CAR-T cell therapy: synthetic genetic switch for spatiotemporal control. Sci. Adv. 10, eadj6251 (2024).","journal-title":"Sci. Adv."},{"key":"2873_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-76258-4","volume":"14","author":"E Yu","year":"2024","unstructured":"Yu, E. et al. Targeting the VEGFR2 signaling pathway for angiogenesis and fibrosis regulation in neovascular age-related macular degeneration. Sci. Rep. 14, 25682 (2024).","journal-title":"Sci. Rep."},{"key":"2873_CR26","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1016\/j.tree.2014.03.002","volume":"29","author":"M Viana","year":"2014","unstructured":"Viana, M. et al. Assembling evidence for identifying reservoirs of infection. Trends Ecol. Evol. 29, 270\u2013279 (2014).","journal-title":"Trends Ecol. Evol."},{"key":"2873_CR27","doi-asserted-by":"publisher","first-page":"e00104","DOI":"10.1128\/mmbr.00104-25","volume":"89","author":"Y Li","year":"2025","unstructured":"Li, Y., Xiao, Q., Yu, F. & Zhang, F. HIV reservoirs in lymphomagenesis: hidden driver in the era of viral suppression? Microbiol. Mol. Biol. Rev. 89, e00104\u2013e00125 (2025).","journal-title":"Microbiol. Mol. Biol. Rev."},{"key":"2873_CR28","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41568-020-0245-2","volume":"20","author":"S M\u00e9ndez-Ferrer","year":"2020","unstructured":"M\u00e9ndez-Ferrer, S. et al. Bone marrow niches in haematological malignancies. Nat. Rev. Cancer 20, 285\u2013298 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"2873_CR29","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/thno.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu, Z. et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics 12, 6273\u20136290 (2022).","journal-title":"Theranostics"},{"key":"2873_CR30","doi-asserted-by":"crossref","unstructured":"Jung, I.-Y. et al. Tissue-resident memory CAR T cells with stem-like characteristics display enhanced efficacy against solid and liquid tumors. Cell Rep. Med. 4, 101053 (2023).","DOI":"10.1016\/j.xcrm.2023.101053"},{"key":"2873_CR31","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.jare.2025.01.004","volume":"77","author":"Y Chen","year":"2025","unstructured":"Chen, Y. et al. Exploring CAR-macrophages in non-tumor diseases: therapeutic potential beyond cancer. J. Adv. Res. 77, 481\u2013496 (2025).","journal-title":"J. Adv. Res."},{"key":"2873_CR32","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1007\/s11904-022-00604-2","volume":"19","author":"EF Kreider","year":"2022","unstructured":"Kreider, E. F. & Bar, K. J. HIV-1 reservoir persistence and decay: implications for cure strategies. Curr. HIV\/AIDS Rep. 19, 194\u2013206 (2022).","journal-title":"Curr. HIV\/AIDS Rep."},{"key":"2873_CR33","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1128\/JVI.77.2.931-942.2003","volume":"77","author":"G Lin","year":"2003","unstructured":"Lin, G. et al. Identification of gp120 binding sites on CXCR4 by using CD4-independent human immunodeficiency virus type 2 Env proteins. J. Virol. 77, 931\u2013942 (2003).","journal-title":"J. Virol."},{"key":"2873_CR34","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1126\/science.1213256","volume":"334","author":"R Pejchal","year":"2011","unstructured":"Pejchal, R. et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science 334, 1097\u20131103 (2011).","journal-title":"Science"},{"key":"2873_CR35","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.1038\/mt.2015.102","volume":"23","author":"A Zhen","year":"2015","unstructured":"Zhen, A. et al. HIV-specific immunity derived from chimeric antigen receptor-engineered stem cells. Mol. Ther. 23, 1358\u20131367 (2015).","journal-title":"Mol. Ther."},{"key":"2873_CR36","doi-asserted-by":"publisher","first-page":"109809","DOI":"10.1016\/j.clim.2023.109809","volume":"257","author":"N Paneerselvam","year":"2023","unstructured":"Paneerselvam, N., Khan, A. & Lawson, B. R. Broadly neutralizing antibodies targeting HIV: progress and challenges. Clin. Immunol. 257, 109809 (2023).","journal-title":"Clin. Immunol."},{"key":"2873_CR37","doi-asserted-by":"crossref","unstructured":"Roselli, E. et al. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells. J. Immunother Cancer. 9, e003354 (2021).","DOI":"10.1136\/jitc-2021-003354"},{"key":"2873_CR38","doi-asserted-by":"publisher","first-page":"1590690","DOI":"10.3389\/fimmu.2025.1590690","volume":"16","author":"JW Wang","year":"2025","unstructured":"Wang, J. W., Liu, J. H. & Xun, J. J. CCR5 gene editing and HIV immunotherapy: current understandings, challenges, and future directions. Front. Immunol. 16, 1590690 (2025).","journal-title":"Front. Immunol."},{"key":"2873_CR39","doi-asserted-by":"crossref","unstructured":"Kansal, R. et al. Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus. Sci. Transl. Med. 11, eaav1648 (2019).","DOI":"10.1126\/scitranslmed.aav1648"},{"key":"2873_CR40","doi-asserted-by":"crossref","unstructured":"Liu, B. et al. Broadly neutralizing antibody-derived CAR T cells reduce viral reservoir in individuals infected with HIV-1. J. Clin. Investig. 131, e150211 (2021).","DOI":"10.1172\/JCI150211"},{"key":"2873_CR41","doi-asserted-by":"publisher","first-page":"410","DOI":"10.3389\/fcimb.2020.00410","volume":"10","author":"W Mu","year":"2020","unstructured":"Mu, W., Carrillo, M. A. & Kitchen, S. G. Engineering CAR T cells to target the HIV reservoir. Front. Cell Infect. Microbiol. 10, 410 (2020).","journal-title":"Front. Cell Infect. Microbiol."},{"key":"2873_CR42","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/j.cell.2019.10.002","volume":"179","author":"E Herzig","year":"2019","unstructured":"Herzig, E. et al. Attacking latent HIV with convertibleCAR-T cells, a highly adaptable killing platform. Cell 179, 880\u2013894 e810 (2019).","journal-title":"Cell"},{"key":"2873_CR43","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1016\/j.ymthe.2016.12.023","volume":"25","author":"M Hale","year":"2017","unstructured":"Hale, M. et al. Engineering HIV-resistant, anti-HIV chimeric antigen receptor T cells. Mol. Ther. 25, 570\u2013579 (2017).","journal-title":"Mol. Ther."},{"key":"2873_CR44","doi-asserted-by":"crossref","unstructured":"Padurariu-Covit, M. D. et al. CAR-T cell therapy for HIV cure: current challenges, advances and future directions. Viruses. 17, 1615 (2025).","DOI":"10.3390\/v17121615"},{"key":"2873_CR45","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/s41421-024-00658-z","volume":"10","author":"Y Mao","year":"2024","unstructured":"Mao, Y. et al. Efficacy and safety of novel multifunctional M10 CAR-T cells in HIV-1-infected patients: a phase I, multicenter, single-arm, open-label study. Cell Discov. 10, 49 (2024).","journal-title":"Cell Discov."},{"key":"2873_CR46","doi-asserted-by":"publisher","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania, B., Kenney, S. C. & Raab-Traub, N. Epstein-Barr virus: biology and clinical disease. Cell 185, 3652\u20133670 (2022).","journal-title":"Cell"},{"key":"2873_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1103695","volume":"14","author":"X Zhang","year":"2023","unstructured":"Zhang, X. et al. GMP development and preclinical validation of CAR-T cells targeting a lytic EBV antigen for therapy of EBV-associated malignancies. Front. Immunol. 14, 1103695 (2023).","journal-title":"Front. Immunol."},{"key":"2873_CR48","doi-asserted-by":"publisher","first-page":"6131","DOI":"10.1093\/emboj\/16.20.6131","volume":"16","author":"O Gires","year":"1997","unstructured":"Gires, O. et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 16, 6131\u20136140 (1997).","journal-title":"EMBO J."},{"key":"2873_CR49","doi-asserted-by":"crossref","unstructured":"Hurwitz, S. N. et al. CD63 regulates Epstein-Barr virus LMP1 exosomal packaging, enhancement of vesicle production, and noncanonical NF-kappaB signaling. J. Virol. 91, e02251-16 (2017).","DOI":"10.1128\/JVI.02251-16"},{"key":"2873_CR50","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.ymthe.2021.10.006","volume":"30","author":"S Harada","year":"2022","unstructured":"Harada, S. et al. Dual-antigen targeted iPSC-derived chimeric antigen receptor-T cell therapy for refractory lymphoma. Mol. Ther. 30, 534\u2013549 (2022).","journal-title":"Mol. Ther."},{"key":"2873_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-025-06188-w","volume":"23","author":"J Wang","year":"2025","unstructured":"Wang, J. et al. Gp350-targeted CAR-T therapy in EBV-positive Burkitt lymphoma: pre-clinical development of gp350 CAR-T. J. Transl. Med. 23, 171 (2025).","journal-title":"J. Transl. Med."},{"key":"2873_CR52","doi-asserted-by":"publisher","first-page":"S1040","DOI":"10.1016\/S2152-2650(25)02826-5","volume":"25","author":"A Khan","year":"2025","unstructured":"Khan, A. et al. CT-1022: clinical outcomes and prognostic impact of Epstein-Barr virus reactivation following CAR T-cell therapy: a systematic review of the Literature. Clin. Lymphoma Myeloma Leuk. 25, S1040 (2025).","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"2873_CR53","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1038\/nrc1452","volume":"4","author":"LS Young","year":"2004","unstructured":"Young, L. S. & Rickinson, A. B. Epstein-Barr virus: 40 years on. Nat. Rev. Cancer 4, 757\u2013768 (2004).","journal-title":"Nat. Rev. Cancer"},{"key":"2873_CR54","doi-asserted-by":"publisher","first-page":"4968","DOI":"10.1016\/j.ymthe.2025.07.044","volume":"33","author":"MM Meehl","year":"2025","unstructured":"Meehl, M. M. et al. Computational structural optimization enhances IL13R\u03b12 - B7-H3 tandem CAR T cells to overcome antigen-heterogeneity-mediated tumor escape. Mol. Ther. 33, 4968\u20134987 (2025).","journal-title":"Mol. Ther."},{"key":"2873_CR55","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/s41586-019-1546-z","volume":"573","author":"H Aghajanian","year":"2019","unstructured":"Aghajanian, H. et al. Targeting cardiac fibrosis with engineered T cells. Nature 573, 430\u2013433 (2019).","journal-title":"Nature"},{"key":"2873_CR56","doi-asserted-by":"publisher","first-page":"515","DOI":"10.6061\/clinics\/2015(07)09","volume":"70","author":"LS Azevedo","year":"2015","unstructured":"Azevedo, L. S. et al. Cytomegalovirus infection in transplant recipients. Clinics 70, 515\u2013523 (2015).","journal-title":"Clinics"},{"key":"2873_CR57","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2404250121","volume":"121","author":"MR Sponholtz","year":"2024","unstructured":"Sponholtz, M. R. et al. Structure-based design of a soluble human cytomegalovirus glycoprotein B antigen stabilized in a prefusion-like conformation. Proc. Natl. Acad. Sci. USA 121, e2404250121 (2024).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2873_CR58","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1089\/hum.2019.149","volume":"31","author":"H Olbrich","year":"2020","unstructured":"Olbrich, H. et al. Adult and cord blood-derived high-affinity gB-CAR-T cells effectively react against human cytomegalovirus infections. Hum. Gene Ther. 31, 423\u2013439 (2020).","journal-title":"Hum. Gene Ther."},{"key":"2873_CR59","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.1016\/j.ymthe.2024.07.020","volume":"32","author":"N Li","year":"2024","unstructured":"Li, N. et al. Armored bicistronic CAR T cells with dominant-negative TGF-beta receptor II to overcome resistance in glioblastoma. Mol. Ther. 32, 3522\u20133538 (2024).","journal-title":"Mol. Ther."},{"key":"2873_CR60","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.virusres.2010.09.011","volume":"157","author":"P Caposio","year":"2011","unstructured":"Caposio, P., Orloff, S. L. & Streblow, D. N. The role of cytomegalovirus in angiogenesis. Virus Res. 157, 204\u2013211 (2011).","journal-title":"Virus Res."},{"key":"2873_CR61","doi-asserted-by":"publisher","first-page":"615","DOI":"10.3324\/haematol.2022.281719","volume":"108","author":"G Chen","year":"2023","unstructured":"Chen, G. et al. Cytomegalovirus reactivation after CD19 CAR T-cell therapy is clinically significant. Haematologica 108, 615\u2013620 (2023).","journal-title":"Haematologica"},{"key":"2873_CR62","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1182\/blood-2023-173926","volume":"142","author":"W Lu","year":"2023","unstructured":"Lu, W. et al. Prophylactic or preemptive donor-derived CD19 CAR-T cell infusion for preventing relapse in high-risk B-ALL after allogeneic hematopoietic stem cell transplantation. Blood 142, 2100 (2023).","journal-title":"Blood"},{"key":"2873_CR63","doi-asserted-by":"crossref","unstructured":"Altrock, P. M. Beyond expansion: tumor debulking as key to improving CAR T-cell potential in lymphoma. Blood Cancer Discov. 7, 11\u201314 (2025).","DOI":"10.1158\/2643-3230.BCD-25-0397"},{"key":"2873_CR64","doi-asserted-by":"publisher","first-page":"8072","DOI":"10.1128\/JVI.00459-07","volume":"81","author":"E Falkowska","year":"2007","unstructured":"Falkowska, E. et al. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 81, 8072\u20138079 (2007).","journal-title":"J. Virol."},{"key":"2873_CR65","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.chom.2018.10.009","volume":"24","author":"AI Flyak","year":"2018","unstructured":"Flyak, A. I. et al. HCV broadly neutralizing antibodies use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design. Cell Host Microbe 24, 703\u2013716 e703 (2018).","journal-title":"Cell Host Microbe"},{"key":"2873_CR66","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1128\/JVI.02837-15","volume":"90","author":"LN Wasilewski","year":"2016","unstructured":"Wasilewski, L. N. et al. A hepatitis C virus envelope polymorphism confers resistance to neutralization by polyclonal sera and broadly neutralizing monoclonal antibodies. J. Virol. 90, 3773\u20133782 (2016).","journal-title":"J. Virol."},{"key":"2873_CR67","doi-asserted-by":"crossref","unstructured":"Saeed, H. et al. Changing landscape of liver transplantation in the post-DAA and contemporary ART era. Life 12, 1755 (2022).","DOI":"10.3390\/life12111755"},{"key":"2873_CR68","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1136\/gutjnl-2014-308316","volume":"65","author":"GA Sautto","year":"2016","unstructured":"Sautto, G. A. et al. Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein. Gut 65, 512\u2013523 (2016).","journal-title":"Gut"},{"key":"2873_CR69","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.28212","volume":"95","author":"X Li","year":"2023","unstructured":"Li, X., Yuan, H., Li, X. & Wang, H. Spike protein mediated membrane fusion during SARS-CoV-2 infection. J. Med. Virol. 95, e28212 (2023).","journal-title":"J. Med. Virol."},{"key":"2873_CR70","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.652223","volume":"12","author":"MT Ma","year":"2021","unstructured":"Ma, M. T. et al. CAR-NK cells effectively target SARS-CoV-2-spike-expressing cell lines in vitro. Front. Immunol. 12, 652223 (2021).","journal-title":"Front. Immunol."},{"key":"2873_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.70038","volume":"14","author":"AS Henden","year":"2025","unstructured":"Henden, A. S. et al. Allogeneic \u2018off-the-shelf\u2019 SARS-CoV-2-specific adoptive T-cell therapy for refractory viral infection and end organ disease. Clin. Transl. Immunol. 14, e70038 (2025).","journal-title":"Clin. Transl. Immunol."},{"key":"2873_CR72","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0002-9440(10)64721-9","volume":"156","author":"A Staratschek-Jox","year":"2000","unstructured":"Staratschek-Jox, A. et al. Detection of Epstein-Barr virus in Hodgkin-Reed-Sternberg cells: no evidence for the persistence of integrated viral fragments in Latent membrane protein-1 (LMP-1)-negative classical Hodgkin\u2019s disease. Am. J. Pathol. 156, 209\u2013216 (2000).","journal-title":"Am. J. Pathol."},{"key":"2873_CR73","doi-asserted-by":"publisher","first-page":"12728","DOI":"10.1182\/blood-2022-157131","volume":"140","author":"M Mei","year":"2022","unstructured":"Mei, M. et al. Phase 1b\/2 study of autologous CD30.CAR-T cells in combination with nivolumab in patients with relapsed or refractory classical Hodgkin lymphoma after failure of frontline therapy (ACTION). Blood 140, 12728\u201312730 (2022).","journal-title":"Blood"},{"key":"2873_CR74","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1016\/j.ymthe.2019.06.007","volume":"27","author":"AA Hombach","year":"2019","unstructured":"Hombach, A. A., Rappl, G. & Abken, H. Blocking CD30 on T cells by a dual specific CAR for CD30 and colon cancer antigens improves the CAR T cell response against CD30(-). Tumors Mol. Ther. 27, 1825\u20131835 (2019).","journal-title":"Tumors Mol. Ther."},{"key":"2873_CR75","doi-asserted-by":"publisher","first-page":"5312","DOI":"10.1182\/bloodadvances.2021004896","volume":"5","author":"L Mikkilineni","year":"2021","unstructured":"Mikkilineni, L. et al. Infectious complications of CAR T-cell therapy across novel antigen targets in the first 30 days. Blood Adv. 5, 5312\u20135322 (2021).","journal-title":"Blood Adv."},{"key":"2873_CR76","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/j.omtm.2022.03.018","volume":"25","author":"J Kath","year":"2022","unstructured":"Kath, J. et al. Pharmacological interventions enhance virus-free generation of TRAC-replaced CAR T cells. Mol. Ther. Methods Clin. Dev. 25, 311\u2013330 (2022).","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"2873_CR77","first-page":"451694","volume":"2011","author":"KA Hofmeyer","year":"2011","unstructured":"Hofmeyer, K. A., Jeon, H. & Zang, X. The PD-1\/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion. J. Biomed. Biotechnol. 2011, 451694 (2011).","journal-title":"J. Biomed. Biotechnol."},{"key":"2873_CR78","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2021.1901434","volume":"10","author":"C Chen","year":"2021","unstructured":"Chen, C. et al. Construction of PD1\/CD28 chimeric-switch receptor enhances anti-tumor ability of c-Met CAR-T in gastric cancer. Oncoimmunology 10, 1901434 (2021).","journal-title":"Oncoimmunology"},{"key":"2873_CR79","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber, D. L. et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682\u2013687 (2006).","journal-title":"Nature"},{"key":"2873_CR80","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.1038\/s41556-024-01465-0","volume":"26","author":"J Majewska","year":"2024","unstructured":"Majewska, J. et al. p16-dependent increase of PD-L1 stability regulates immunosurveillance of senescent cells. Nat. Cell Biol. 26, 1336\u20131345 (2024).","journal-title":"Nat. Cell Biol."},{"key":"2873_CR81","doi-asserted-by":"publisher","first-page":"229","DOI":"10.21037\/tcr.2016.06.25","volume":"5","author":"M Chmielewski","year":"2016","unstructured":"Chmielewski, M. & Abken, H. Release brakes: chimeric antigen receptor T cells with PD-1 switch receptor. Transl. Cancer Res. 5, 229\u2013232 (2016).","journal-title":"Transl. Cancer Res."},{"key":"2873_CR82","doi-asserted-by":"crossref","unstructured":"Yoshimoto, S. et al. Validation of a PD-1\/CD28 chimeric switch receptor to augment CAR-T function in dogs with spontaneous B cell lymphoma. iScience 27, 110863 (2024).","DOI":"10.1016\/j.isci.2024.110863"},{"key":"2873_CR83","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","volume":"1","author":"LG Guidotti","year":"2006","unstructured":"Guidotti, L. G. & Chisari, F. V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. 1, 23\u201361 (2006).","journal-title":"Annu. Rev. Pathol."},{"key":"2873_CR84","doi-asserted-by":"publisher","first-page":"10660","DOI":"10.1073\/pnas.1312789111","volume":"111","author":"PR Kumaresan","year":"2014","unstructured":"Kumaresan, P. R. et al. Bioengineering T cells to target carbohydrate to treat opportunistic fungal infection. Proc. Natl. Acad. Sci. USA 111, 10660\u201310665 (2014).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2873_CR85","doi-asserted-by":"publisher","first-page":"14270","DOI":"10.1073\/pnas.1111415108","volume":"108","author":"A Esteban","year":"2011","unstructured":"Esteban, A. et al. Fungal recognition is mediated by the association of dectin-1 and galectin-3 in macrophages. Proc. Natl. Acad. Sci. USA 108, 14270\u201314275 (2011).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"2873_CR86","doi-asserted-by":"publisher","first-page":"673","DOI":"10.3389\/fimmu.2018.00673","volume":"9","author":"G Camilli","year":"2018","unstructured":"Camilli, G., Tabouret, G. & Quintin, J. The complexity of fungal beta-glucan in health and disease: effects on the mononuclear phagocyte system. Front. Immunol. 9, 673 (2018).","journal-title":"Front. Immunol."},{"key":"2873_CR87","doi-asserted-by":"publisher","first-page":"e120","DOI":"10.1371\/journal.ppat.0020120","volume":"2","author":"LE Yauch","year":"2006","unstructured":"Yauch, L. E., Lam, J. S. & Levitz, S. M. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan. PLoS Pathog. 2, e120 (2006).","journal-title":"PLoS Pathog."},{"key":"2873_CR88","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41422-023-00789-0","volume":"33","author":"J Chen","year":"2023","unstructured":"Chen, J. et al. Tuning charge density of chimeric antigen receptor optimizes tonic signaling and CAR-T cell fitness. Cell Res. 33, 341\u2013354 (2023).","journal-title":"Cell Res."},{"key":"2873_CR89","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17970-3","volume":"11","author":"B Salzer","year":"2020","unstructured":"Salzer, B. et al. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. Nat. Commun. 11, 4166 (2020).","journal-title":"Nat. Commun."},{"key":"2873_CR90","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1128\/IAI.02493-14","volume":"83","author":"A Welin","year":"2015","unstructured":"Welin, A. et al. CFP-10 from Mycobacterium tuberculosis selectively activates human neutrophils through a pertussis toxin-sensitive chemotactic receptor. Infect. Immun. 83, 205\u2013213 (2015).","journal-title":"Infect. Immun."},{"key":"2873_CR91","doi-asserted-by":"crossref","unstructured":"Anes, E., Pires, D., Mandal, M. & Azevedo-Pereira, J. M. ESAT-6 a major virulence factor of mycobacterium tuberculosis. Biomolecules. 13,968 (2023).","DOI":"10.3390\/biom13060968"},{"key":"2873_CR92","first-page":"204993612110367","volume":"8","author":"AG Stewart","year":"2021","unstructured":"Stewart, A. G. & Henden, A. S. Infectious complications of CAR T-cell therapy: a clinical update. Ther. Adv. Infect. Dis. 8, 20499361211036773 (2021).","journal-title":"Ther. Adv. Infect. Dis."},{"key":"2873_CR93","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.immuni.2017.04.008","volume":"46","author":"Y Belkaid","year":"2017","unstructured":"Belkaid, Y. & Harrison, O. J. Homeostatic immunity and the microbiota. Immunity 46, 562\u2013576 (2017).","journal-title":"Immunity"},{"key":"2873_CR94","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1126\/science.284.5418.1318","volume":"284","author":"JW Costerton","year":"1999","unstructured":"Costerton, J. W., Stewart, P. S. & Greenberg, E. P. Bacterial biofilms: a common cause of persistent infections. Science 284, 1318\u20131322 (1999).","journal-title":"Science"},{"key":"2873_CR95","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","volume":"38","author":"M Klichinsky","year":"2020","unstructured":"Klichinsky, M. et al. Human chimeric antigen receptor macrophages for cancer immunotherapy. Nat. Biotechnol. 38, 947\u2013953 (2020).","journal-title":"Nat. Biotechnol."},{"key":"2873_CR96","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jaut.2009.09.008","volume":"33","author":"GS Cooper","year":"2009","unstructured":"Cooper, G. S., Bynum, M. L. & Somers, E. C. Recent insights in the epidemiology of autoimmune diseases: improved prevalence estimates and understanding of clustering of diseases. J. Autoimmun. 33, 197\u2013207 (2009).","journal-title":"J. Autoimmun."},{"key":"2873_CR97","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1056\/NEJM200108023450506","volume":"345","author":"A Davidson","year":"2001","unstructured":"Davidson, A. & Diamond, B. Autoimmune diseases. N. Engl. J. Med. 345, 340\u2013350 (2001).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR98","first-page":"171","volume":"129","author":"GS Firestein","year":"2018","unstructured":"Firestein, G. S. Pathogenesis of rheumatoid arthritis: the intersection of genetics and epigenetics. Trans. Am. Clin. Climatol. Assoc. 129, 171\u2013182 (2018).","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"key":"2873_CR99","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/nrrheum.2011.1","volume":"7","author":"F Hiepe","year":"2011","unstructured":"Hiepe, F. et al. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat. Rev. Rheumatol. 7, 170\u2013178 (2011).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2873_CR100","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/art.21650","volume":"54","author":"G Cambridge","year":"2006","unstructured":"Cambridge, G. et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. Arthritis Rheum. 54, 723\u2013732 (2006).","journal-title":"Arthritis Rheum."},{"key":"2873_CR101","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1002\/eji.200939500","volume":"39","author":"K Tokoyoda","year":"2009","unstructured":"Tokoyoda, K., Zehentmeier, S., Chang, H.-D. & Radbruch, A. Organization and maintenance of immunological memory by stroma niches. Eur. J. Immunol. 39, 2095\u20132099 (2009).","journal-title":"Eur. J. Immunol."},{"key":"2873_CR102","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/ard.2009.123919","volume":"69","author":"JS Smolen","year":"2010","unstructured":"Smolen, J. S. et al. Treating rheumatoid arthritis to target: recommendations of an international task force. Ann. Rheum. Dis. 69, 631\u2013637 (2010).","journal-title":"Ann. Rheum. Dis."},{"key":"2873_CR103","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1126\/science.aar6711","volume":"359","author":"CH June","year":"2018","unstructured":"June, C. H. et al. CAR T cell immunotherapy for human cancer. Science 359, 1361\u20131365 (2018).","journal-title":"Science"},{"key":"2873_CR104","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen, A. et al. Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat. Med 28, 2124\u20132132 (2022).","journal-title":"Nat. Med"},{"key":"2873_CR105","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1056\/NEJMoa2308917","volume":"390","author":"F M\u00fcller","year":"2024","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N. Engl. J. Med. 390, 687\u2013700 (2024).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR106","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.1016\/S0140-6736(23)01126-1","volume":"402","author":"G Schett","year":"2023","unstructured":"Schett, G., Mackensen, A. & Mougiakakos, D. CAR T-cell therapy in autoimmune diseases. Lancet 402, 2034\u20132044 (2023).","journal-title":"Lancet"},{"key":"2873_CR107","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/2162-3619-1-36","volume":"1","author":"K Wang","year":"2012","unstructured":"Wang, K., Wei, G. & Liu, D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp. Hematol. Oncol. 1, 36 (2012).","journal-title":"Exp. Hematol. Oncol."},{"key":"2873_CR108","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1053\/j.gastro.2025.11.013","volume":"170","author":"I Marafini","year":"2025","unstructured":"Marafini, I., Salvatori, S., Troncone, E. & Monteleone, G. CD19 CAR T-cell therapy for refractory ulcerative colitis. Gastroenterology 170, 665\u2013667 (2025).","journal-title":"Gastroenterology"},{"key":"2873_CR109","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1056\/NEJMc2508023","volume":"393","author":"F M\u00fcller","year":"2025","unstructured":"M\u00fcller, F. et al. CD19 CAR T-cell therapy in multidrug-resistant ulcerative colitis. N. Engl. J. Med. 393, 1239\u20131241 (2025).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR110","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1038\/nri3700","volume":"14","author":"C Pitzalis","year":"2014","unstructured":"Pitzalis, C., Jones, G. W., Bombardieri, M. & Jones, S. A. Ectopic lymphoid-like structures in infection, cancer and autoimmunity. Nat. Rev. Immunol. 14, 447\u2013462 (2014).","journal-title":"Nat. Rev. Immunol."},{"key":"2873_CR111","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1186\/ar1799","volume":"7","author":"I Sanz","year":"2005","unstructured":"Sanz, I. & Anolik, J. Reconstitution of the adult B cell repertoire after treatment with rituximab. Arthritis Res Ther. 7, 175\u2013176 (2005).","journal-title":"Arthritis Res Ther."},{"key":"2873_CR112","doi-asserted-by":"publisher","first-page":"S162","DOI":"10.1016\/j.jtct.2025.01.249","volume":"31","author":"D Mougiakakos","year":"2025","unstructured":"Mougiakakos, D. et al. Successful generation of anti-CD19 CAR T-cells (KYV-101) for clinical use in patients with clinically diverse autoimmune disorders. Transplant. Cell. Ther. 31, S162\u2013S163 (2025).","journal-title":"Transplant. Cell. Ther."},{"key":"2873_CR113","doi-asserted-by":"publisher","first-page":"27","DOI":"10.3899\/jrheum.2025-0390.O029","volume":"52","author":"S Sheikh","year":"2025","unstructured":"Sheikh, S. et al. RESET SLE: CLINICAL TRIAL EVALUATING CABA-201, A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN NONRENAL SLE AND LUPUS NEPHRITIS. J. Rheumatol. 52, 27\u201327 (2025).","journal-title":"J. Rheumatol."},{"key":"2873_CR114","doi-asserted-by":"publisher","first-page":"2088","DOI":"10.1182\/blood-2024-194525","volume":"144","author":"F Mueller","year":"2024","unstructured":"Mueller, F. et al. Tolerability, efficacy, pharmacokinetics, and pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor (CAR) T cell therapy manufactured using a next-generation process, for severe, refractory autoimmune diseases: updated data from ongoing phase 1, multicenter, open-label studies. Blood 144, 2088 (2024).","journal-title":"Blood"},{"key":"2873_CR115","doi-asserted-by":"crossref","first-page":"582.e581","DOI":"10.1016\/j.jtct.2024.03.023","volume":"30","author":"J Dingfelder","year":"2024","unstructured":"Dingfelder, J. et al. Fully human anti-CD19 CAR T cells derived from systemic lupus erythematosus patients exhibit cytotoxicity with reduced inflammatory cytokine production. Transplant. Cell. Ther. 30, 582.e581\u2013582.e510 (2024).","journal-title":"Transplant. Cell. Ther."},{"key":"2873_CR116","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.molmed.2019.11.003","volume":"26","author":"A Bar-Or","year":"2020","unstructured":"Bar-Or, A. et al. Epstein-Barr virus in multiple sclerosis: theory and emerging immunotherapies. Trends Mol. Med. 26, 296\u2013310 (2020).","journal-title":"Trends Mol. Med."},{"key":"2873_CR117","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1056\/NEJMoa0706383","volume":"358","author":"SL Hauser","year":"2008","unstructured":"Hauser, S. L. et al. B-cell depletion with rituximab in relapsing\u2013remitting multiple sclerosis. N. Engl. J. Med. 358, 676\u2013688 (2008).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR118","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ebiom.2017.01.042","volume":"16","author":"D Baker","year":"2017","unstructured":"Baker, D. et al. Memory B cells are major targets for effective immunotherapy in relapsing multiple sclerosis. EBioMedicine 16, 41\u201350 (2017).","journal-title":"EBioMedicine"},{"key":"2873_CR119","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi, R. et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130, 1089\u20131104 (2007).","journal-title":"Brain"},{"key":"2873_CR120","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","volume":"5","author":"F Fischbach","year":"2024","unstructured":"Fischbach, F. et al. CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis. Med 5, 550\u2013558.e552 (2024).","journal-title":"Med"},{"key":"2873_CR121","doi-asserted-by":"publisher","first-page":"5371","DOI":"10.1212\/WNL.0000000000212317","volume":"104","author":"J Dunn","year":"2025","unstructured":"Dunn, J. et al. A phase 1, open-label, single center study of KYV-101, an autologous fully-human anti-CD19 chimeric antigen receptor T-cell (CD19 CAR T) therapy, in subjects with non-relapsing and progressive forms of multiple sclerosis (S3.001). Neurology 104, 5371 (2025).","journal-title":"Neurology"},{"key":"2873_CR122","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","volume":"25","author":"DW Lee","year":"2019","unstructured":"Lee, D. W. et al. ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol. Blood Marrow Transpl. 25, 625\u2013638 (2019).","journal-title":"Biol. Blood Marrow Transpl."},{"key":"2873_CR123","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","volume":"7","author":"J Gust","year":"2017","unstructured":"Gust, J. et al. Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells. Cancer Discov. 7, 1404\u20131419 (2017).","journal-title":"Cancer Discov."},{"key":"2873_CR124","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/S0140-6736(23)00023-5","volume":"401","author":"F M\u00fcller","year":"2023","unstructured":"M\u00fcller, F. et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet 401, 815\u2013818 (2023).","journal-title":"Lancet"},{"key":"2873_CR125","doi-asserted-by":"publisher","first-page":"6048","DOI":"10.1093\/rheumatology\/keaf455","volume":"64","author":"C Ciurtin","year":"2025","unstructured":"Ciurtin, C., Sparchez, M., Elephtheriou, D. & Brogan, P. The evolving landscape of rheumatic drugs and their indications in paediatric and adolescent care. Rheumatology 64, 6048\u20136070 (2025).","journal-title":"Rheumatology"},{"key":"2873_CR126","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2538350","volume":"21","author":"M Jiang","year":"2025","unstructured":"Jiang, M. et al. Research progress on chimeric antigen receptor-based immunotherapy against autoimmune diseases. Hum. Vaccin Immunother. 21, 2538350 (2025).","journal-title":"Hum. Vaccin Immunother."},{"key":"2873_CR127","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.1111\/all.16585","volume":"80","author":"F Rossi","year":"2025","unstructured":"Rossi, F., Fernandez Santamaria, R. & Castagnoli, R. CAR-T cell therapy in autoimmune setting: a new appealing approach extendable to allergy? Allergy 80, 2421\u20132422 (2025).","journal-title":"Allergy"},{"key":"2873_CR128","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1007\/s10753-024-02052-z","volume":"48","author":"Z Pan","year":"2025","unstructured":"Pan, Z. et al. Peripheral blood lymphocyte subsets and heterogeneity of B cell subsets in patients of idiopathic inflammatory myositis with different myositis-specific autoantibodies. Inflammation 48, 118\u2013132 (2025).","journal-title":"Inflammation"},{"key":"2873_CR129","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1172\/JCI31139","volume":"117","author":"J Varga","year":"2007","unstructured":"Varga, J. & Abraham, D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J. Clin. Investig. 117, 557\u2013567 (2007).","journal-title":"J. Clin. Investig."},{"key":"2873_CR130","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1084\/jem.20031330","volume":"199","author":"BP O\u2019Connor","year":"2004","unstructured":"O\u2019Connor, B. P. et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J. Exp. Med. 199, 91\u201398 (2004).","journal-title":"J. Exp. Med."},{"key":"2873_CR131","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/nri2572","volume":"9","author":"F Mackay","year":"2009","unstructured":"Mackay, F. & Schneider, P. Cracking the BAFF code. Nat. Rev. Immunol. 9, 491\u2013502 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2873_CR132","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N. Engl. J. Med. 385, 567\u2013569 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR133","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","volume":"84","author":"Z Hu","year":"2025","unstructured":"Hu, Z. et al. BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann. Rheum. Dis. 84, 1675\u20131683 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"2873_CR134","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR135","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1172\/JCI126397","volume":"129","author":"AD Cohen","year":"2019","unstructured":"Cohen, A. D. et al. B cell maturation antigen-specific CAR T cells are clinically active in multiple myeloma. J. Clin. Investig. 129, 2210\u20132221 (2019).","journal-title":"J. Clin. Investig."},{"key":"2873_CR136","doi-asserted-by":"publisher","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","volume":"365","author":"AD Stasi","year":"2011","unstructured":"Stasi, A. D. et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365, 1673\u20131683 (2011).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR137","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1126\/science.abm0594","volume":"375","author":"JG Rurik","year":"2022","unstructured":"Rurik, J. G. et al. CAR T cells produced in vivo to treat cardiac injury. Science 375, 91\u201396 (2022).","journal-title":"Science"},{"key":"2873_CR138","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1038\/nri1886","volume":"6","author":"A Radbruch","year":"2006","unstructured":"Radbruch, A. et al. Competence and competition: the challenge of becoming a long-lived plasma cell. Nat. Rev. Immunol. 6, 741\u2013750 (2006).","journal-title":"Nat. Rev. Immunol."},{"key":"2873_CR139","doi-asserted-by":"publisher","first-page":"3612","DOI":"10.1002\/art.22211","volume":"54","author":"G Cambridge","year":"2006","unstructured":"Cambridge, G. et al. B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles. Arthritis Rheum. 54, 3612\u20133622 (2006).","journal-title":"Arthritis Rheum."},{"key":"2873_CR140","doi-asserted-by":"publisher","first-page":"2378","DOI":"10.1182\/blood-2025-2378","volume":"146","author":"S Elias","year":"2025","unstructured":"Elias, S. et al. BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: initial results from a phase 1 clinical trial. Blood 146, 2378\u20132378 (2025).","journal-title":"Blood"},{"key":"2873_CR141","doi-asserted-by":"publisher","first-page":"2146","DOI":"10.1002\/art.11181","volume":"48","author":"G Cambridge","year":"2003","unstructured":"Cambridge, G. et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum. 48, 2146\u20132154 (2003).","journal-title":"Arthritis Rheum."},{"key":"2873_CR142","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/art.43212","volume":"77","author":"LR Sammaritano","year":"2025","unstructured":"Sammaritano, L. R. et al. 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol. 77, 1115\u20131135 (2025).","journal-title":"Arthritis Rheumatol."},{"key":"2873_CR143","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1517\/14712598.2015.1009888","volume":"15","author":"M Ruella","year":"2015","unstructured":"Ruella, M. & Gill, S. How to train your T cell: genetically engineered chimeric antigen receptor T cells versus bispecific T-cell engagers to target CD19 in B acute lymphoblastic leukemia. Expert Opin. Biol. Ther. 15, 761\u2013766 (2015).","journal-title":"Expert Opin. Biol. Ther."},{"key":"2873_CR144","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","volume":"8","author":"RG Majzner","year":"2018","unstructured":"Majzner, R. G. & Mackall, C. L. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 8, 1219\u20131226 (2018).","journal-title":"Cancer Discov."},{"key":"2873_CR145","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrrheum.2015.159","volume":"12","author":"A Davidson","year":"2016","unstructured":"Davidson, A. What is damaging the kidney in lupus nephritis? Nat. Rev. Rheumatol. 12, 143\u2013153 (2016).","journal-title":"Nat. Rev. Rheumatol."},{"key":"2873_CR146","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1084\/jem.20040168","volume":"199","author":"BF Hoyer","year":"2004","unstructured":"Hoyer, B. F. et al. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB\/W mice. J. Exp. Med. 199, 1577\u20131584 (2004).","journal-title":"J. Exp. Med."},{"key":"2873_CR147","doi-asserted-by":"publisher","first-page":"ii35","DOI":"10.1093\/ckj\/sfaf290","volume":"18","author":"D Lodka","year":"2025","unstructured":"Lodka, D. & Schreiber, A. CAR-T cells targeting CD19 for the treatment of ANCA vasculitis. Clin. Kidney J. 18, ii35\u2013ii46 (2025).","journal-title":"Clin. Kidney J."},{"key":"2873_CR148","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1053\/j.ajkd.2019.10.017","volume":"76","author":"SV Parikh","year":"2020","unstructured":"Parikh, S. V., Almaani, S., Brodsky, S. & Rovin, B. H. Update on lupus nephritis: core curriculum 2020. Am. J. Kidney Dis. 76, 265\u2013281 (2020).","journal-title":"Am. J. Kidney Dis."},{"key":"2873_CR149","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1186\/ar3433","volume":"13","author":"T D\u00f6rner","year":"2011","unstructured":"D\u00f6rner, T., Giesecke, C. & Lipsky, P. E. Mechanisms of B cell autoimmunity in SLE. Arthritis Res. Ther. 13, 243 (2011).","journal-title":"Arthritis Res. Ther."},{"key":"2873_CR150","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.4049\/jimmunol.1001983","volume":"186","author":"A Chang","year":"2011","unstructured":"Chang, A. et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J. Immunol. 186, 1849\u20131860 (2011).","journal-title":"J. Immunol."},{"key":"2873_CR151","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1084\/jem.20111675","volume":"209","author":"TA Barr","year":"2012","unstructured":"Barr, T. A. et al. B cell depletion therapy ameliorates autoimmune disease through ablation of IL-6-producing B cells. J. Exp. Med. 209, 1001\u20131010 (2012).","journal-title":"J. Exp. Med."},{"key":"2873_CR152","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/ard-2023-224875","volume":"83","author":"D Lodka","year":"2024","unstructured":"Lodka, D. et al. CD19-targeting CAR T cells protect from ANCA-induced acute kidney injury. Ann. Rheum. Dis. 83, 499\u2013507 (2024).","journal-title":"Ann. Rheum. Dis."},{"key":"2873_CR153","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1126\/science.aaf6756","volume":"353","author":"CT Ellebrecht","year":"2016","unstructured":"Ellebrecht, C. T. et al. Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science 353, 179\u2013184 (2016).","journal-title":"Science"},{"key":"2873_CR154","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1335998","volume":"15","author":"L Perico","year":"2024","unstructured":"Perico, L. et al. Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases. Front. Immunol. 15, 1335998 (2024).","journal-title":"Front. Immunol."},{"key":"2873_CR155","doi-asserted-by":"crossref","unstructured":"Nunez, D. et al. CD19 CAR T therapy is feasible in patients with pemphigus vulgaris treated without lymphodepletion in the RESET-PV trial. Blood blood.2025032093 (2026).","DOI":"10.1182\/blood.2025032093"},{"key":"2873_CR156","doi-asserted-by":"publisher","first-page":"5084","DOI":"10.1016\/j.cell.2023.10.001","volume":"186","author":"SM Reincke","year":"2023","unstructured":"Reincke, S. M. et al. Chimeric autoantibody receptor T cells deplete NMDA receptor-specific B cells. Cell 186, 5084\u20135097.e5018 (2023).","journal-title":"Cell"},{"key":"2873_CR157","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1038\/s41587-022-01637-z","volume":"41","author":"S Oh","year":"2023","unstructured":"Oh, S. et al. Precision targeting of autoantigen-specific B cells in muscle-specific tyrosine kinase myasthenia gravis with chimeric autoantibody receptor T cells. Nat. Biotechnol. 41, 1229\u20131238 (2023).","journal-title":"Nat. Biotechnol."},{"key":"2873_CR158","unstructured":"ClinicalTrials.gov. MuSK-CAART for Myasthenia Gravis. Identifier: NCT05451719."},{"key":"2873_CR159","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/S1474-4422(23)00194-1","volume":"22","author":"V Granit","year":"2023","unstructured":"Granit, V. et al. Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis (MG-001): a prospective, multicentre, open-label, non-randomised phase 1b\/2a study. Lancet Neurol. 22, 578\u2013590 (2023).","journal-title":"Lancet Neurol."},{"key":"2873_CR160","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","volume":"32","author":"T Vu","year":"2026","unstructured":"Vu, T. et al. BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat. Med. 32, 1131\u20131141 (2026).","journal-title":"Nat. Med."},{"key":"2873_CR161","doi-asserted-by":"publisher","first-page":"2561","DOI":"10.1016\/j.ymthe.2026.04.008","volume":"34","author":"JF Howard","year":"2026","unstructured":"Howard, J. F. Descartes-08: unlocking the potential of mRNA CAR T-cell therapy in myasthenia gravis. Mol. Ther. 34, 2561\u20132563 (2026).","journal-title":"Mol. Ther."},{"key":"2873_CR162","doi-asserted-by":"publisher","first-page":"2080","DOI":"10.1182\/blood-2024-203585","volume":"144","author":"MD Miljkovic","year":"2024","unstructured":"Miljkovic, M. D. et al. Safety and tolerability of BCMA-directed mRNA CAR T-cell therapy in multiple myeloma and autoimmune disease. Blood 144, 2080 (2024).","journal-title":"Blood"},{"key":"2873_CR163","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.05.017","volume":"103","author":"M Tenspolde","year":"2019","unstructured":"Tenspolde, M. et al. Regulatory T cells engineered with a novel insulin-specific chimeric antigen receptor as a candidate immunotherapy for type 1 diabetes. J. Autoimmun. 103, 102289 (2019).","journal-title":"J. Autoimmun."},{"key":"2873_CR164","doi-asserted-by":"publisher","first-page":"315ra189","DOI":"10.1126\/scitranslmed.aad4134","volume":"7","author":"JA Bluestone","year":"2015","unstructured":"Bluestone, J. A. et al. Type 1 diabetes immunotherapy using polyclonal regulatory T cells. Sci. Transl. Med. 7, 315ra189\u2013315ra189 (2015).","journal-title":"Sci. Transl. Med."},{"key":"2873_CR165","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.2337\/dc12-0038","volume":"35","author":"N Marek-Trzonkowska","year":"2012","unstructured":"Marek-Trzonkowska, N. et al. Administration of CD4+CD25highCD127- regulatory T cells preserves \u03b2-cell function in type 1 diabetes in children. Diab. Care 35, 1817\u20131820 (2012).","journal-title":"Diab. Care"},{"key":"2873_CR166","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-024-03262-w","volume":"21","author":"J Frikeche","year":"2024","unstructured":"Frikeche, J. et al. MOG-specific CAR Tregs: a novel approach to treat multiple sclerosis. J. Neuroinflammation 21, 268 (2024).","journal-title":"J. Neuroinflammation"},{"key":"2873_CR167","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellimm.2020.104222","volume":"358","author":"A De Paula Pohl","year":"2020","unstructured":"De Paula Pohl, A. et al. Engineered regulatory T cells expressing myelin-specific chimeric antigen receptors suppress EAE progression. Cell Immunol. 358, 104222 (2020).","journal-title":"Cell Immunol."},{"key":"2873_CR168","doi-asserted-by":"publisher","DOI":"10.1186\/1742-2094-9-112","volume":"9","author":"M Fransson","year":"2012","unstructured":"Fransson, M. et al. CAR\/FoxP3-engineered T regulatory cells target the CNS and suppress EAE upon intranasal delivery. J. Neuroinflammation 9, 112 (2012).","journal-title":"J. Neuroinflammation"},{"key":"2873_CR169","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1182\/blood-2004-09-3579","volume":"105","author":"DJ Mekala","year":"2005","unstructured":"Mekala, D. J. & Geiger, T. L. Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes. Blood 105, 2090\u20132092 (2005).","journal-title":"Blood"},{"key":"2873_CR170","first-page":"76","volume":"11","author":"S Taherkhani","year":"2025","unstructured":"Taherkhani, S., Honardoost, M., Dokhani, N. & Janzadeh, A. Revolutionizing cardiac fibrosis treatment: the potential of personalized CAR T-cell therapy. Cardiooncology 11, 76 (2025).","journal-title":"Cardiooncology"},{"key":"2873_CR171","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR172","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-11-245","volume":"11","author":"HO Lee","year":"2011","unstructured":"Lee, H. O. et al. FAP-overexpressing fibroblasts produce an extracellular matrix that enhances invasive velocity and directionality of pancreatic cancer cells. BMC Cancer 11, 245 (2011).","journal-title":"BMC Cancer"},{"key":"2873_CR173","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2024.200817","volume":"32","author":"L Zhou","year":"2024","unstructured":"Zhou, L. et al. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma. Mol. Ther. Oncol. 32, 200817 (2024).","journal-title":"Mol. Ther. Oncol."},{"key":"2873_CR174","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2024.116604","volume":"230","author":"Y Mao","year":"2024","unstructured":"Mao, Y. et al. Targeting fibroblast activation protein with chimeric antigen receptor macrophages. Biochem. Pharm. 230, 116604 (2024).","journal-title":"Biochem. Pharm."},{"key":"2873_CR175","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s41030-023-00226-y","volume":"9","author":"S Duong-Quy","year":"2023","unstructured":"Duong-Quy, S. et al. Post-COVID-19 pulmonary fibrosis: facts-challenges and futures: a narrative review. Pulm. Ther. 9, 295\u2013307 (2023).","journal-title":"Pulm. Ther."},{"key":"2873_CR176","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.stem.2014.11.004","volume":"16","author":"R Kramann","year":"2015","unstructured":"Kramann, R. et al. Perivascular Gli1+ progenitors are key contributors to injury-induced organ fibrosis. Cell Stem Cell 16, 51\u201366 (2015).","journal-title":"Cell Stem Cell"},{"key":"2873_CR177","doi-asserted-by":"publisher","first-page":"1617","DOI":"10.1038\/nm.3282","volume":"19","author":"NC Henderson","year":"2013","unstructured":"Henderson, N. C. et al. Targeting of \u03b1v integrin identifies a core molecular pathway that regulates fibrosis in several organs. Nat. Med. 19, 1617\u20131624 (2013).","journal-title":"Nat. Med."},{"key":"2873_CR178","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15+ myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, 232\u2013253 (2020).","journal-title":"Cancer Discov."},{"key":"2873_CR179","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1111\/j.1745-7254.2007.00468.x","volume":"28","author":"L Gu","year":"2007","unstructured":"Gu, L. et al. Effect of TGF-beta\/Smad signaling pathway on lung myofibroblast differentiation. Acta Pharm. Sin. 28, 382\u2013391 (2007).","journal-title":"Acta Pharm. Sin."},{"key":"2873_CR180","doi-asserted-by":"publisher","first-page":"3556","DOI":"10.1158\/1078-0432.CCR-20-4513","volume":"27","author":"GD Demetri","year":"2021","unstructured":"Demetri, G. D. et al. First-in-human phase I study of ABBV-085, an antibody-drug conjugate targeting LRRC15, in sarcomas and other advanced solid tumors. Clin. Cancer Res. 27, 3556\u20133566 (2021).","journal-title":"Clin. Cancer Res."},{"key":"2873_CR181","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1038\/s41586-022-05272-1","volume":"611","author":"AT Krishnamurty","year":"2022","unstructured":"Krishnamurty, A. T. et al. LRRC15+ myofibroblasts dictate the stromal setpoint to suppress tumour immunity. Nature 611, 148\u2013154 (2022).","journal-title":"Nature"},{"key":"2873_CR182","doi-asserted-by":"publisher","first-page":"L824","DOI":"10.1152\/ajplung.00350.2015","volume":"310","author":"KH Sun","year":"2016","unstructured":"Sun, K. H., Chang, Y., Reed, N. I. & Sheppard, D. -Smooth muscle actin is an inconsistent marker of fibroblasts responsible for force-dependent TGF\u03b2 activation or collagen production across multiple models of organ fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 310, L824\u2013836 (2016).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2873_CR183","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-19-0644","volume":"10","author":"CX Dominguez","year":"2020","unstructured":"Dominguez, C. X. et al. Single-cell RNA sequencing reveals stromal evolution into LRRC15(+) myofibroblasts as a determinant of patient response to cancer immunotherapy. Cancer Discov. 10, 232\u2013253 (2020).","journal-title":"Cancer Discov."},{"key":"2873_CR184","first-page":"714","volume":"6","author":"H Fan","year":"2014","unstructured":"Fan, H. et al. Role of PDGFR-beta\/PI3K\/AKT signaling pathway in PDGF-BB induced myocardial fibrosis in rats. Am. J. Transl. Res. 6, 714\u2013723 (2014).","journal-title":"Am. J. Transl. Res."},{"key":"2873_CR185","doi-asserted-by":"publisher","first-page":"e0209786","DOI":"10.1371\/journal.pone.0209786","volume":"13","author":"M Kishi","year":"2018","unstructured":"Kishi, M. et al. Blockade of platelet-derived growth factor receptor-beta, not receptor-alpha ameliorates bleomycin-induced pulmonary fibrosis in mice. PLoS ONE 13, e0209786 (2018).","journal-title":"PLoS ONE"},{"key":"2873_CR186","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1165\/rcmb.2013-0455OC","volume":"51","author":"Y Aono","year":"2014","unstructured":"Aono, Y. et al. Role of platelet-derived growth factor\/platelet-derived growth factor receptor axis in the trafficking of circulating fibrocytes in pulmonary fibrosis. Am. J. Respir. Cell Mol. Biol. 51, 793\u2013801 (2014).","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"2873_CR187","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1158\/2326-6066.CIR-13-0027","volume":"2","author":"LC Wang","year":"2014","unstructured":"Wang, L. C. et al. Targeting fibroblast activation protein in tumor stroma with chimeric antigen receptor T cells can inhibit tumor growth and augment host immunity without severe toxicity. Cancer Immunol. Res. 2, 154\u2013166 (2014).","journal-title":"Cancer Immunol. Res."},{"key":"2873_CR188","doi-asserted-by":"crossref","unstructured":"Wang, Z. et al. Pdgfr\u03b2 marks distinct mesenchymal and pericyte populations within the periosteum with overlapping cellular features. Stem Cells. 43, sxaf020 (2025).","DOI":"10.1093\/stmcls\/sxaf020"},{"key":"2873_CR189","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2353\/ajpath.2010.090517","volume":"176","author":"BD Humphreys","year":"2010","unstructured":"Humphreys, B. D. et al. Fate tracing reveals the pericyte and not epithelial origin of myofibroblasts in kidney fibrosis. Am. J. Pathol. 176, 85\u201397 (2010).","journal-title":"Am. J. Pathol."},{"key":"2873_CR190","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1172\/JCI200522675","volume":"115","author":"JS Duffield","year":"2005","unstructured":"Duffield, J. S. et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J. Clin. Invest 115, 56\u201365 (2005).","journal-title":"J. Clin. Invest"},{"key":"2873_CR191","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41573-023-00846-8","volume":"23","author":"YR Miao","year":"2024","unstructured":"Miao, Y. R., Rankin, E. B. & Giaccia, A. J. Therapeutic targeting of the functionally elusive TAM receptor family. Nat. Rev. Drug Discov. 23, 201\u2013217 (2024).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2873_CR192","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1531294","volume":"15","author":"Z Zhang","year":"2024","unstructured":"Zhang, Z. et al. A self-activated and protective module enhances the preclinical performance of allogeneic anti-CD70 CAR-T cells. Front. Immunol. 15, 1531294 (2024).","journal-title":"Front. Immunol."},{"key":"2873_CR193","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jhep.2015.04.013","volume":"63","author":"C Barcena","year":"2015","unstructured":"Barcena, C. et al. Gas6\/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation. J. Hepatol. 63, 670\u2013678 (2015).","journal-title":"J. Hepatol."},{"key":"2873_CR194","doi-asserted-by":"publisher","first-page":"101400","DOI":"10.1016\/j.jceh.2024.101400","volume":"14","author":"MH Ali","year":"2024","unstructured":"Ali, M. H., Talha, M. & Hussain, S. A. S. The role of hepatic stellate cells and the Gas6\/Axl axis in liver fibrosis and hepatocellular carcinoma. J. Clin. Exp. Hepatol. 14, 101400 (2024).","journal-title":"J. Clin. Exp. Hepatol."},{"key":"2873_CR195","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.jcmgh.2023.03.007","volume":"16","author":"OT Pop","year":"2023","unstructured":"Pop, O. T. et al. AXL expression on homeostatic resident liver macrophages is reduced in cirrhosis following GAS6 production by hepatic stellate cells. Cell Mol. Gastroenterol. Hepatol. 16, 17\u201337 (2023).","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"2873_CR196","doi-asserted-by":"crossref","unstructured":"Ceraolo, M. G. et al. CSPG4.CAR-T cells modulate extracellular matrix remodeling in DMD cardiomyopathy. Int. J. Mol. Sci. 26, 6590 (2025).","DOI":"10.3390\/ijms26146590"},{"key":"2873_CR197","doi-asserted-by":"publisher","first-page":"L344","DOI":"10.1152\/ajplung.00300.2014","volume":"308","author":"F Liu","year":"2015","unstructured":"Liu, F. et al. Mechanosignaling through YAP and TAZ drives fibroblast activation and fibrosis. Am. J. Physiol. Lung Cell Mol. Physiol. 308, L344\u2013L357 (2015).","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"2873_CR198","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1164\/rccm.201204-0754OC","volume":"186","author":"AJ Booth","year":"2012","unstructured":"Booth, A. J. et al. Acellular normal and fibrotic human lung matrices as a culture system for in vitro investigation. Am. J. Respir. Crit. Care Med. 186, 866\u2013876 (2012).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"2873_CR199","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1083\/jcb.200704042","volume":"179","author":"PJ Wipff","year":"2007","unstructured":"Wipff, P. J., Rifkin, D. B., Meister, J. J. & Hinz, B. Myofibroblast contraction activates latent TGF-beta1 from the extracellular matrix. J. Cell Biol. 179, 1311\u20131323 (2007).","journal-title":"J. Cell Biol."},{"key":"2873_CR200","first-page":"H61","volume":"326","author":"MB Felisbino","year":"2024","unstructured":"Felisbino, M. B. et al. Substrate stiffness modulates cardiac fibroblast activation, senescence, and proinflammatory secretory phenotype. Am. J. Physiol. Heart Circ. Physiol. 326, H61\u2013H73 (2024).","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"2873_CR201","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/1471-2466-14-120","volume":"14","author":"S Estany","year":"2014","unstructured":"Estany, S. et al. Lung fibrotic tenascin-C upregulation is associated with other extracellular matrix proteins and induced by TGFbeta1. BMC Pulm. Med. 14, 120 (2014).","journal-title":"BMC Pulm. Med."},{"key":"2873_CR202","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1564998","volume":"16","author":"R Tomai","year":"2025","unstructured":"Tomai, R. et al. Challenges in the preclinical design and assessment of CAR-T cells. Front. Immunol. 16, 1564998 (2025).","journal-title":"Front. Immunol."},{"key":"2873_CR203","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/cvr\/cvu053","volume":"102","author":"V Sarrazy","year":"2014","unstructured":"Sarrazy, V. et al. Integrins alphaVbeta5 and alphaVbeta3 promote latent TGF-beta1 activation by human cardiac fibroblast contraction. Cardiovasc. Res. 102, 407\u2013417 (2014).","journal-title":"Cardiovasc. Res."},{"key":"2873_CR204","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1158\/0008-5472.CAN-16-1911","volume":"78","author":"TT Byrd","year":"2018","unstructured":"Byrd, T. T. et al. TEM8\/ANTXR1-specific CAR T cells as a targeted therapy for triple-negative breast cancer. Cancer Res. 78, 489\u2013500 (2018).","journal-title":"Cancer Res."},{"key":"2873_CR205","doi-asserted-by":"publisher","first-page":"3953","DOI":"10.1172\/JCI43490","volume":"120","author":"D Chinnasamy","year":"2010","unstructured":"Chinnasamy, D. et al. Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice. J. Clin. Investig. 120, 3953\u20133968 (2010).","journal-title":"J. Clin. Investig."},{"key":"2873_CR206","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1158\/1078-0432.CCR-11-3050","volume":"18","author":"D Chinnasamy","year":"2012","unstructured":"Chinnasamy, D. et al. Local delivery of interleukin-12 using T cells targeting VEGF receptor-2 eradicates multiple vascularized tumors in mice. Clin. Cancer Res. 18, 1672\u20131683 (2012).","journal-title":"Clin. Cancer Res."},{"key":"2873_CR207","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1021\/acs.molpharmaceut.0c01182","volume":"18","author":"J Zhou","year":"2021","unstructured":"Zhou, J. et al. Targeting interstitial myofibroblast-expressed integrin alphavbeta3 alleviates renal fibrosis. Mol. Pharm. 18, 1373\u20131385 (2021).","journal-title":"Mol. Pharm."},{"key":"2873_CR208","doi-asserted-by":"crossref","unstructured":"Rossato, F. A., Su, Y., Mackey, A. & Ng, Y. S. E. Fibrotic changes and endothelial-to-mesenchymal transition promoted by VEGFR2 antagonism alter the therapeutic effects of vegfa pathway blockage in a mouse model of choroidal neovascularization. Cells. 9, 2057 (2020).","DOI":"10.3390\/cells9092057"},{"key":"2873_CR209","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.2147\/DDDT.S415453","volume":"17","author":"YL Luo","year":"2023","unstructured":"Luo, Y. L. et al. Inhibition of LPA-LPAR1 and VEGF-VEGFR2 signaling in IPF treatment. Drug Des. Devel Ther. 17, 2679\u20132690 (2023).","journal-title":"Drug Des. Devel Ther."},{"key":"2873_CR210","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13045-018-0568-6","volume":"11","author":"J Li","year":"2018","unstructured":"Li, J. et al. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J. Hematol. Oncol. 11, 22 (2018).","journal-title":"J. Hematol. Oncol."},{"key":"2873_CR211","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cels.2020.08.002","volume":"11","author":"R Dannenfelser","year":"2020","unstructured":"Dannenfelser, R. et al. Discriminatory power of combinatorial antigen recognition in cancer T cell therapies. Cell Syst. 11, 215\u2013228.e215 (2020).","journal-title":"Cell Syst."},{"key":"2873_CR212","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-07824-5","volume":"16","author":"L M\u00f6bus","year":"2025","unstructured":"M\u00f6bus, L. et al. Endothelial sensitivity to pro-fibrotic signals links systemic exposure to pulmonary fibrosis. Cell Death Dis. 16, 500 (2025).","journal-title":"Cell Death Dis."},{"key":"2873_CR213","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1111\/j.1478-3231.2010.02347.x","volume":"31","author":"BL Copple","year":"2011","unstructured":"Copple, B. L., Bai, S., Burgoon, L. D. & Moon, J. O. Hypoxia-inducible factor-1\u03b1 regulates the expression of genes in hypoxic hepatic stellate cells important for collagen deposition and angiogenesis. Liver Int. 31, 230\u2013244 (2011).","journal-title":"Liver Int."},{"key":"2873_CR214","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1111\/imm.13888","volume":"174","author":"S Zhu","year":"2025","unstructured":"Zhu, S. et al. Co-expression of dominant-negative TGF-beta receptor 2 enhances the therapeutic efficacy of novel TREM1\/DAP12-BB-based CAR-T cells in solid tumours. Immunology 174, 310\u2013321 (2025).","journal-title":"Immunology"},{"key":"2873_CR215","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","volume":"26","author":"CC Kloss","year":"2018","unstructured":"Kloss, C. C. et al. Dominant-negative TGF-\u03b2 receptor enhances PSMA-targeted human CAR T cell proliferation and augments prostate cancer eradication. Mol. Ther. 26, 1855\u20131866 (2018).","journal-title":"Mol. Ther."},{"key":"2873_CR216","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41591-022-01726-1","volume":"28","author":"V Narayan","year":"2022","unstructured":"Narayan, V. et al. PSMA-targeting TGF\u03b2-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial. Nat. Med 28, 724\u2013734 (2022).","journal-title":"Nat. Med"},{"key":"2873_CR217","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","volume":"388","author":"F Peyvandi","year":"2016","unstructured":"Peyvandi, F., Garagiola, I. & Young, G. The past and future of haemophilia: diagnosis, treatments, and its complications. Lancet 388, 187\u2013197 (2016).","journal-title":"Lancet"},{"key":"2873_CR218","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1182\/blood-2018-08-872291","volume":"133","author":"AC Weyand","year":"2019","unstructured":"Weyand, A. C. & Pipe, S. W. New therapies for hemophilia. Blood 133, 389\u2013398 (2019).","journal-title":"Blood"},{"key":"2873_CR219","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1056\/NEJMoa1803550","volume":"379","author":"J Mahlangu","year":"2018","unstructured":"Mahlangu, J. et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N. Engl. J. Med. 379, 811\u2013822 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR220","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/bjh.12463","volume":"162","author":"WC P","year":"2013","unstructured":"P, W. C. et al. Diagnosis and management of acquired coagulation inhibitors: a guideline from UKHCDO. Br. J. Haematol. 162, 758\u2013773 (2013).","journal-title":"Br. J. Haematol."},{"key":"2873_CR221","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1703068","volume":"377","author":"J Oldenburg","year":"2017","unstructured":"Oldenburg, J. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N. Engl. J. Med. 377, 809\u2013818 (2017).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR222","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3324\/haematol.2018.206383","volume":"104","author":"V Aditi","year":"2019","unstructured":"Aditi, V. & S\u00e9bastien, L.-D. Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance? Haematologica 104, 236\u2013244 (2019).","journal-title":"Haematologica"},{"key":"2873_CR223","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1111\/j.1538-7836.2011.04267.x","volume":"9","author":"B Pautard","year":"2011","unstructured":"Pautard, B. et al. Successful immune tolerance induction by FVIII in hemophilia A patients with inhibitor may occur without deletion of FVIII-specific T cells. J. J. Thromb. Haemost. 9, 1163\u20131170 (2011).","journal-title":"J. J. Thromb. Haemost."},{"key":"2873_CR224","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1056\/NEJMoa1208024","volume":"368","author":"SC Gouw","year":"2013","unstructured":"Gouw, S. C. et al. Factor VIII products and inhibitor development in severe hemophilia A. N. Engl. J. Med. 368, 231\u2013239 (2013).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR225","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1182\/blood-2008-02-124941","volume":"112","author":"S Lacroix-Desmazes","year":"2008","unstructured":"Lacroix-Desmazes, S. et al. Dynamics of factor VIII interactions determine its immunologic fate in hemophilia A. Blood 112, 240\u2013249 (2008).","journal-title":"Blood"},{"key":"2873_CR226","doi-asserted-by":"publisher","first-page":"4234","DOI":"10.1182\/blood-2007-06-096842","volume":"110","author":"SL Meeks","year":"2007","unstructured":"Meeks, S. L. et al. Antihuman factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 110, 4234\u20134242 (2007).","journal-title":"Blood"},{"key":"2873_CR227","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1160\/TH08-08-0508","volume":"101","author":"S Gharagozlou","year":"2009","unstructured":"Gharagozlou, S. et al. Epitope specificity of anti-factor VIII antibodies from inhibitor positive acquired and congenital haemophilia A patients using synthetic peptides spanning A and C domains. Thromb. Haemost. 101, 834\u2013839 (2009).","journal-title":"Thromb. Haemost."},{"key":"2873_CR228","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1111\/j.1538-7836.2007.02736.x","volume":"5","author":"PM van Helden","year":"2007","unstructured":"van Helden, P. M. et al. Factor VIII-specific memory B cells in patients with hemophilia A. J. Thromb. Haemost. 5, 2306\u20132308 (2007).","journal-title":"J. Thromb. Haemost."},{"key":"2873_CR229","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1182\/blood-2005-03-1182","volume":"106","author":"C Hausl","year":"2005","unstructured":"Hausl, C. et al. High-dose factor VIII inhibits factor VIII-specific memory B cells in hemophilia A with factor VIII inhibitors. Blood 106, 3415\u20133422 (2005).","journal-title":"Blood"},{"key":"2873_CR230","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George, L. A. et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N. Engl. J. Med 377, 2215\u20132227 (2017).","journal-title":"N. Engl. J. Med"},{"key":"2873_CR231","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1182\/bloodadvances.2018018556","volume":"2","author":"K Parvathaneni","year":"2018","unstructured":"Parvathaneni, K. & Scott, D. W. Engineered FVIII-expressing cytotoxic T cells target and kill FVIII-specific B cells in vitro and in vivo. Blood Adv. 2, 2332\u20132340 (2018).","journal-title":"Blood Adv."},{"key":"2873_CR232","doi-asserted-by":"publisher","first-page":"854","DOI":"10.1046\/j.1365-2516.1998.00190.x","volume":"4","author":"L Tengborn","year":"1998","unstructured":"Tengborn, L. et al. Anaphylactoid reactions and nephrotic syndrome-a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers. Haemophilia 4, 854\u2013859 (1998).","journal-title":"Haemophilia"},{"key":"2873_CR233","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1097\/00043426-199701000-00003","volume":"19","author":"I Warrier","year":"1997","unstructured":"Warrier, I. et al. Factor IX inhibitors and anaphylaxis in hemophilia B. J. Pediatr. Hematol. Oncol. 19, 23\u201327 (1997).","journal-title":"J. Pediatr. Hematol. Oncol."},{"key":"2873_CR234","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/mt.2014.43","volume":"22","author":"X Wang","year":"2014","unstructured":"Wang, X. et al. Immune tolerance induction to factor IX through B cell gene transfer: TLR9 signaling delineates between tolerogenic and immunogenic B cells. Mol. Ther. 22, 1139\u20131150 (2014).","journal-title":"Mol. Ther."},{"key":"2873_CR235","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1046\/j.1365-2516.2002.00587.x","volume":"8","author":"MV Ragni","year":"2002","unstructured":"Ragni, M. V. et al. Use of recombinant factor IX in subjects with haemophilia B undergoing surgery. Haemophilia 8, 91\u201397 (2002).","journal-title":"Haemophilia"},{"key":"2873_CR236","doi-asserted-by":"publisher","first-page":"3389","DOI":"10.1182\/blood-2014-07-580498","volume":"124","author":"PW Collins","year":"2014","unstructured":"Collins, P. W. et al. Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011. Blood 124, 3389\u20133397 (2014).","journal-title":"Blood"},{"key":"2873_CR237","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1182\/bloodadvances.2018019323","volume":"2","author":"CL Kempton","year":"2018","unstructured":"Kempton, C. L. & Payne, A. B. HLA-DRB1-factor VIII binding is a risk factor for inhibitor development in nonsevere hemophilia: a case-control study. Blood Adv. 2, 1750\u20131755 (2018).","journal-title":"Blood Adv."},{"key":"2873_CR238","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1182\/blood-2015-11-682468","volume":"128","author":"RA Ettinger","year":"2016","unstructured":"Ettinger, R. A. et al. T cells from hemophilia A subjects recognize the same HLA-restricted FVIII epitope with a narrow TCR repertoire. Blood 128, 2043\u20132054 (2016).","journal-title":"Blood"},{"key":"2873_CR239","doi-asserted-by":"publisher","first-page":"2226","DOI":"10.1172\/JCI27620","volume":"116","author":"S Tollefsen","year":"2006","unstructured":"Tollefsen, S. et al. HLA-DQ2 and -DQ8 signatures of gluten T cell epitopes in celiac disease. J. Clin. Investig. 116, 2226\u20132236 (2006).","journal-title":"J. Clin. Investig."},{"key":"2873_CR240","doi-asserted-by":"publisher","first-page":"e236","DOI":"10.1111\/j.1365-2516.2011.02604.x","volume":"18","author":"MF De Barros","year":"2012","unstructured":"De Barros, M. F. et al. Influence of class I and II HLA alleles on inhibitor development in severe haemophilia A patients from the south of Brazil. Haemophilia 18, e236\u2013e240 (2012).","journal-title":"Haemophilia"},{"key":"2873_CR241","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1056\/NEJMra1802677","volume":"379","author":"A Loupy","year":"2018","unstructured":"Loupy, A. & Lefaucheur, C. Antibody-mediated rejection of solid-organ allografts. N. Engl. J. Med. 379, 1150\u20131160 (2018).","journal-title":"N. Engl. J. Med."},{"key":"2873_CR242","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1007\/s00467-008-1020-x","volume":"25","author":"E Ingulli","year":"2010","unstructured":"Ingulli, E. Mechanism of cellular rejection in transplantation. Pediatr. Nephrol. 25, 61\u201374 (2010).","journal-title":"Pediatr. Nephrol."},{"key":"2873_CR243","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2174\/187153011795564197","volume":"11","author":"KC Chiang","year":"2011","unstructured":"Chiang, K. C., Ohmori, N. & Goto, T. The search for immunosuppressive therapies to induce tolerance in organ transplantation. Endocr. Metab. Immune Disord. Drug Targets 11, 173\u2013180 (2011).","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"key":"2873_CR244","doi-asserted-by":"publisher","first-page":"a015487","DOI":"10.1101\/cshperspect.a015487","volume":"3","author":"C Hartono","year":"2013","unstructured":"Hartono, C., Muthukumar, T. & Suthanthiran, M. Immunosuppressive drug therapy. Cold Spring Harb. Perspect. Med 3, a015487 (2013).","journal-title":"Cold Spring Harb. Perspect. Med"},{"key":"2873_CR245","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/s41551-019-0359-6","volume":"3","author":"DA Boardman","year":"2019","unstructured":"Boardman, D. A. & Levings, M. K. Cancer immunotherapies repurposed for use in autoimmunity. Nat. Biomed. Eng. 3, 259\u2013263 (2019).","journal-title":"Nat. Biomed. Eng."},{"key":"2873_CR246","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nm1251","volume":"11","author":"RI Lechler","year":"2005","unstructured":"Lechler, R. I., Sykes, M., Thomson, A. W. & Turka, L. A. Organ transplantation-how much of the promise has been realized? Nat. Med. 11, 605\u2013613 (2005).","journal-title":"Nat. Med."},{"key":"2873_CR247","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/ajt.14185","volume":"17","author":"DA Boardman","year":"2017","unstructured":"Boardman, D. A. et al. Expression of a chimeric antigen receptor specific for donor HLA class I enhances the potency of human regulatory T cells in preventing human skin transplant rejection. Am. J. Transpl. 17, 931\u2013943 (2017).","journal-title":"Am. J. Transpl."},{"key":"2873_CR248","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1172\/JCI82771","volume":"126","author":"KG MacDonald","year":"2016","unstructured":"MacDonald, K. G. et al. Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor. J. Clin. Investig. 126, 1413\u20131424 (2016).","journal-title":"J. Clin. Investig."},{"key":"2873_CR249","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1111\/ajt.14175","volume":"17","author":"F Noyan","year":"2017","unstructured":"Noyan, F. et al. Prevention of allograft rejection by use of regulatory T cells with an MHC-specific chimeric antigen receptor. Am. J. Transpl. 17, 917\u2013930 (2017).","journal-title":"Am. J. Transpl."},{"key":"2873_CR250","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1038\/nri2526","volume":"9","author":"M Croft","year":"2009","unstructured":"Croft, M. The role of TNF superfamily members in T-cell function and diseases. Nat. Rev. Immunol. 9, 271\u2013285 (2009).","journal-title":"Nat. Rev. Immunol."},{"key":"2873_CR251","doi-asserted-by":"crossref","unstructured":"Kitchens, W. H. et al. Interruption of OX40L signaling prevents costimulation blockade\u2013resistant allograft rejection. JCI Insight. 2, e90317 (2017).","DOI":"10.1172\/jci.insight.90317"},{"key":"2873_CR252","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/nri2153","volume":"7","author":"SD Miller","year":"2007","unstructured":"Miller, S. D., Turley, D. M. & Podojil, J. R. Antigen-specific tolerance strategies for the prevention and treatment of autoimmune disease. Nat. Rev. Immunol. 7, 665\u2013677 (2007).","journal-title":"Nat. Rev. Immunol."},{"key":"2873_CR253","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/S0065-2776(10)05003-0","volume":"105","author":"N Ishii","year":"2010","unstructured":"Ishii, N., Takahashi, T., Soroosh, P. & Sugamura, K. OX40-OX40 ligand interaction in T-cell-mediated immunity and immunopathology. Adv. Immunol. 105, 63\u201398 (2010).","journal-title":"Adv. Immunol."},{"key":"2873_CR254","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.immuni.2015.06.016","volume":"43","author":"JL Halliley","year":"2015","unstructured":"Halliley, J. L. et al. Long-lived plasma cells are contained within the CD19(-)CD38(hi)CD138(+) subset in human bone marrow. Immunity 43, 132\u2013145 (2015).","journal-title":"Immunity"},{"key":"2873_CR255","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/j.1600-6143.2006.01288.x","volume":"6","author":"MD Pescovitz","year":"2006","unstructured":"Pescovitz, M. D. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am. J. Transpl. 6, 859\u2013866 (2006).","journal-title":"Am. J. Transpl."},{"key":"2873_CR256","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.1182\/blood-2004-07-2507","volume":"105","author":"M Odendahl","year":"2005","unstructured":"Odendahl, M. et al. Generation of migratory antigen-specific plasma blasts and mobilization of resident plasma cells in a secondary immune response. Blood 105, 1614\u20131621 (2005).","journal-title":"Blood"},{"key":"2873_CR257","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1146\/annurev-immunol-041015-055605","volume":"34","author":"CG Vinuesa","year":"2016","unstructured":"Vinuesa, C. G., Linterman, M. A., Yu, D. & MacLennan, I. C. Follicular helper T cells. Annu Rev. Immunol. 34, 335\u2013368 (2016).","journal-title":"Annu Rev. Immunol."},{"key":"2873_CR258","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/TP.0b013e3181b96646","volume":"88","author":"J Kwun","year":"2009","unstructured":"Kwun, J. & Knechtle, S. J. Overcoming chronic rejection-can it B? Transplantation 88, 955\u2013961 (2009).","journal-title":"Transplantation"},{"key":"2873_CR259","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.adj9331","volume":"16","author":"X Rui","year":"2024","unstructured":"Rui, X. et al. Human OX40L-CAR-T(regs) target activated antigen-presenting cells and control T cell alloreactivity. Sci. Transl. Med. 16, eadj9331 (2024).","journal-title":"Sci. Transl. Med."},{"key":"2873_CR260","doi-asserted-by":"publisher","first-page":"3821","DOI":"10.4049\/jimmunol.154.8.3821","volume":"154","author":"LJ Zhou","year":"1995","unstructured":"Zhou, L. J. & Tedder, T. F. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J. Immunol. 154, 3821\u20133835 (1995).","journal-title":"J. Immunol."},{"key":"2873_CR261","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.imlet.2011.01.013","volume":"136","author":"B Kretschmer","year":"2011","unstructured":"Kretschmer, B., K\u00fchl, S., Fleischer, B. & Breloer, M. Activated T cells induce rapid CD83 expression on B cells by engagement of CD40. Immunol. Lett. 136, 221\u2013227 (2011).","journal-title":"Immunol. Lett."},{"key":"2873_CR262","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1002\/eji.200636535","volume":"37","author":"C Aerts-Toegaert","year":"2007","unstructured":"Aerts-Toegaert, C. et al. CD83 expression on dendritic cells and T cells: correlation with effective immune responses. Eur. J. Immunol. 37, 686\u2013695 (2007).","journal-title":"Eur. J. Immunol."},{"key":"2873_CR263","first-page":"232","volume":"25","author":"M Thurnher","year":"1997","unstructured":"Thurnher, M. et al. In vitro generation of CD83+ human blood dendritic cells for active tumor immunotherapy. Exp. Hematol. 25, 232\u2013237 (1997).","journal-title":"Exp. Hematol."},{"key":"2873_CR264","doi-asserted-by":"publisher","first-page":"4652","DOI":"10.1172\/JCI135754","volume":"130","author":"B Shrestha","year":"2020","unstructured":"Shrestha, B. et al. Human CD83-targeted chimeric antigen receptor T cells prevent and treat graft-versus-host disease. J. Clin. Investig. 130, 4652\u20134662 (2020).","journal-title":"J. Clin. Investig."},{"key":"2873_CR265","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1016\/j.cell.2008.05.009","volume":"133","author":"S Sakaguchi","year":"2008","unstructured":"Sakaguchi, S., Yamaguchi, T., Nomura, T. & Ono, M. Regulatory T cells and immune tolerance. Cell 133, 775\u2013787 (2008).","journal-title":"Cell"},{"key":"2873_CR266","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1016\/j.it.2011.04.002","volume":"32","author":"SL Bailey-Bucktrout","year":"2011","unstructured":"Bailey-Bucktrout, S. L. & Bluestone, J. A. Regulatory T cells: stability revisited. Trends Immunol. 32, 301\u2013306 (2011).","journal-title":"Trends Immunol."},{"key":"2873_CR267","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1038\/s41573-019-0041-4","volume":"18","author":"LMR Ferreira","year":"2019","unstructured":"Ferreira, L. M. R., Muller, Y. D., Bluestone, J. A. & Tang, Q. Next-generation regulatory T cell therapy. Nat. Rev. Drug Discov. 18, 749\u2013769 (2019).","journal-title":"Nat. Rev. Drug Discov."},{"key":"2873_CR268","doi-asserted-by":"crossref","unstructured":"Zhang, L. et al. Cellular senescence: a key therapeutic target in aging and diseases. J. Clin. Investig. 132, e158450 (2022).","DOI":"10.1172\/JCI158450"},{"key":"2873_CR269","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1101\/gad.353125.125","volume":"39","author":"J Gil","year":"2025","unstructured":"Gil, J. The interplay between senescence, inflammation, and the immune system. Genes Dev. 39, 923\u2013925 (2025).","journal-title":"Genes Dev."},{"key":"2873_CR270","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.trsl.2020.06.007","volume":"226","author":"J Kaur","year":"2020","unstructured":"Kaur, J. & Farr, J. N. Cellular senescence in age-related disorders. Transl. Res. 226, 96\u2013104 (2020).","journal-title":"Transl. Res."},{"key":"2873_CR271","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/s43587-025-01022-w","volume":"6","author":"O Eskiocak","year":"2026","unstructured":"Eskiocak, O. et al. Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness. Nat. Aging 6, 108\u2013126 (2026).","journal-title":"Nat. Aging"},{"key":"2873_CR272","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/s43587-024-00576-5","volume":"4","author":"JM Bartley","year":"2024","unstructured":"Bartley, J. M. & Xu, M. Unleashing CAR T cells to delay metabolic aging. Nat. Aging 4, 284\u2013286 (2024).","journal-title":"Nat. Aging"},{"key":"2873_CR273","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1160\/TH12-08-0546","volume":"109","author":"N Montuori","year":"2013","unstructured":"Montuori, N. et al. uPAR regulates pericellular proteolysis through a mechanism involving integrins and fMLF-receptors. Thromb. Haemost. 109, 309\u2013318 (2013).","journal-title":"Thromb. Haemost."},{"key":"2873_CR274","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1038\/s43587-023-00560-5","volume":"4","author":"C Amor","year":"2024","unstructured":"Amor, C. et al. Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction. Nat. Aging 4, 336\u2013349 (2024).","journal-title":"Nat. Aging"},{"key":"2873_CR275","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2020.107503","volume":"209","author":"S Shao","year":"2020","unstructured":"Shao, S. et al. Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions. Pharm. Ther. 209, 107503 (2020).","journal-title":"Pharm. Ther."},{"key":"2873_CR276","doi-asserted-by":"publisher","first-page":"63","DOI":"10.4093\/dmj.2020.0253","volume":"46","author":"S Hong","year":"2022","unstructured":"Hong, S., Jung, C. H., Han, S. & Park, C. Y. Increasing age associated with higher dipeptidyl peptidase-4 inhibition rate is a predictive factor for efficacy of dipeptidyl peptidase-4 inhibitors. Diab. Metab. J. 46, 63\u201370 (2022).","journal-title":"Diab. Metab. J."},{"key":"2873_CR277","doi-asserted-by":"publisher","first-page":"10204","DOI":"10.1182\/blood-2022-163679","volume":"140","author":"S Zhang","year":"2022","unstructured":"Zhang, S. et al. The in vitro and in vivo effects of DPP-4 inhibition with sitagliptin, alone and in combination with bortezomib, on T cell activation: rationale for GvHD prevention. Blood 140, 10204\u201310205 (2022).","journal-title":"Blood"},{"key":"2873_CR278","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti, I. et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal. Transduct. Target. Ther. 10, 210 (2025).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"2873_CR279","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1101\/gad.313270.118","volume":"32","author":"KM Kim","year":"2018","unstructured":"Kim, K. M. et al. SCAMP4 enhances the senescent cell secretome. Genes Dev. 32, 909\u2013914 (2018).","journal-title":"Genes Dev."},{"key":"2873_CR280","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.add1951","volume":"15","author":"D Yang","year":"2023","unstructured":"Yang, D. et al. NKG2D-CAR T cells eliminate senescent cells in aged mice and nonhuman primates. Sci. Transl. Med. 15, eadd1951 (2023).","journal-title":"Sci. Transl. Med."},{"key":"2873_CR281","doi-asserted-by":"publisher","first-page":"e191","DOI":"10.1016\/S2352-3026(22)00378-7","volume":"10","author":"DA Sallman","year":"2023","unstructured":"Sallman, D. A. et al. CYAD-01, an autologous NKG2D-based CAR T-cell therapy, in relapsed or refractory acute myeloid leukaemia and myelodysplastic syndromes or multiple myeloma (THINK): haematological cohorts of the dose escalation segment of a phase 1 trial. Lancet Haematol. 10, e191\u2013e202 (2023).","journal-title":"Lancet Haematol."},{"key":"2873_CR282","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/nm.3898","volume":"21","author":"LK Smith","year":"2015","unstructured":"Smith, L. K. et al. Beta2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis. Nat. Med. 21, 932\u2013937 (2015).","journal-title":"Nat. Med."},{"key":"2873_CR283","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.trecan.2024.11.010","volume":"11","author":"L Zhou","year":"2025","unstructured":"Zhou, L., Ma, B. & Ruscetti, M. Cellular senescence offers distinct immunological vulnerabilities in cancer. Trends Cancer 11, 334\u2013350 (2025).","journal-title":"Trends Cancer"},{"key":"2873_CR284","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0014-5793(03)01370-X","volume":"556","author":"J Cichy","year":"2004","unstructured":"Cichy, J. & Pur\u00e9, E. Cytokines regulate the affinity of soluble CD44 for hyaluronan. FEBS Lett. 556, 69\u201374 (2004).","journal-title":"FEBS Lett."},{"key":"2873_CR285","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.108255","volume":"301","author":"LC Duke","year":"2025","unstructured":"Duke, L. C. et al. Tetraspanin CD9 alters cellular trafficking and endocytosis of tetraspanin CD63, affecting CD63 packaging into small extracellular vesicles. J. Biol. Chem. 301, 108255 (2025).","journal-title":"J. Biol. Chem."},{"key":"2873_CR286","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1089\/hum.2020.216","volume":"32","author":"A Stornaiuolo","year":"2021","unstructured":"Stornaiuolo, A. et al. Characterization and functional analysis of CD44v6.CAR T cells endowed with a new low-affinity nerve growth factor receptor-based spacer. Hum. Gene Ther. 32, 744\u2013760 (2021).","journal-title":"Hum. Gene Ther."},{"key":"2873_CR287","doi-asserted-by":"publisher","first-page":"2953","DOI":"10.1084\/jem.20061151","volume":"203","author":"X Liu","year":"2006","unstructured":"Liu, X. et al. Bcl-xl does not have to bind Bax to protect T cells from death. J. Exp. Med. 203, 2953\u20132961 (2006).","journal-title":"J. Exp. Med."},{"key":"2873_CR288","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/S1470-2045(10)70261-8","volume":"11","author":"WH Wilson","year":"2010","unstructured":"Wilson, W. H. et al. Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol. 11, 1149\u20131159 (2010).","journal-title":"Lancet Oncol."},{"key":"2873_CR289","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00109-024-02444-6","volume":"102","author":"A Salminen","year":"2024","unstructured":"Salminen, A. The role of the immunosuppressive PD-1\/PD-L1 checkpoint pathway in the aging process and age-related diseases. J. Mol. Med. 102, 733\u2013750 (2024).","journal-title":"J. Mol. Med."},{"key":"2873_CR290","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02419-2","volume":"24","author":"T Feng","year":"2025","unstructured":"Feng, T. et al. Cellular senescence in cancer: from mechanism paradoxes to precision therapeutics. Mol. Cancer 24, 213 (2025).","journal-title":"Mol. Cancer"},{"key":"2873_CR291","doi-asserted-by":"publisher","DOI":"10.3389\/fmedt.2024.1384648","volume":"6","author":"PV Peplow","year":"2024","unstructured":"Peplow, P. V. Reprogramming T cells as an emerging treatment to slow human age-related decline in health. Front. Med. Technol. 6, 1384648 (2024).","journal-title":"Front. Med. Technol."},{"key":"2873_CR292","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.omto.2020.08.005","volume":"18","author":"C Slabik","year":"2020","unstructured":"Slabik, C. et al. CAR-T cells targeting Epstein-Barr virus gp350 validated in a humanized mouse model of EBV infection and lymphoproliferative disease. Mol. Ther. Oncol. 18, 504\u2013524 (2020).","journal-title":"Mol. Ther. Oncol."},{"key":"2873_CR293","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.00038-24","volume":"98","author":"MT Ma","year":"2024","unstructured":"Ma, M. T. et al. S309-CAR-NK cells bind the Omicron variants in vitro and reduce SARS-CoV-2 viral loads in humanized ACE2-NSG mice. J. Virol. 98, e0003824 (2024).","journal-title":"J. Virol."},{"key":"2873_CR294","doi-asserted-by":"crossref","unstructured":"Ogando-Rivas, E. et al. Expanded specific T cells to hypomutated regions of the SARS-CoV-2 using mRNA electroporated antigen-presenting cells. Mol. Ther. Methods Clin. Dev. 32, 101192 (2024).","DOI":"10.1016\/j.omtm.2024.101192"},{"key":"2873_CR295","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2023.2281059","volume":"14","author":"MP Machado","year":"2023","unstructured":"Machado, M. P. et al. GXMR-CAR containing distinct GXM-specific single-chain variable fragment (scFv) mediated the cell activation against Cryptococcus spp. And had difference in the strength of tonic signaling. Bioengineered 14, 2281059 (2023).","journal-title":"Bioengineered"},{"key":"2873_CR296","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1038\/s41417-021-00418-1","volume":"29","author":"M Sheykhhasan","year":"2022","unstructured":"Sheykhhasan, M., Manoochehri, H. & Dama, P. Use of CAR T-cell for acute lymphoblastic leukemia (ALL) treatment: a review study. Cancer Gene Ther. 29, 1080\u20131096 (2022).","journal-title":"Cancer Gene Ther."},{"key":"2873_CR297","doi-asserted-by":"publisher","first-page":"3794","DOI":"10.1200\/JCO.20.01342","volume":"38","author":"CA Ramos","year":"2020","unstructured":"Ramos, C. A. et al. Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma. J. Clin. Oncol. 38, 3794\u20133804 (2020).","journal-title":"J. Clin. Oncol."},{"key":"2873_CR298","doi-asserted-by":"crossref","unstructured":"Bates, T. A. et al. ESAT-6 undergoes self-association at phagosomal pH, and an ESAT-6 specific nanobody restricts M. tuberculosis growth in macrophages. bioRxiv (2024).","DOI":"10.7554\/eLife.91930.2"},{"key":"2873_CR299","doi-asserted-by":"publisher","first-page":"3469.3461","DOI":"10.1182\/blood-2024-204169","volume":"144","author":"MR Seshadri","year":"2024","unstructured":"Seshadri, M. R. et al. A study of Kyv-101, a CD19 CAR T cell therapy, in participants with treatment refractory progressive multiple sclerosis. Blood 144, 3469.3461 (2024).","journal-title":"Blood"},{"key":"2873_CR300","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.jtct.2025.12.014","volume":"32","author":"R Reshef","year":"2026","unstructured":"Reshef, R. et al. Clinical outcomes from the pooled safety analysis of CD19 Nex-TTM (BMS-986353), a Chimeric Antigen Receptor (CAR) T cell therapy manufactured using a next-generation process, in severe refractory autoimmune diseases: results from phase 1 breakfree studies. Transplant. Cell. Ther. 32, S1 (2026).","journal-title":"Transplant. Cell. Ther."},{"key":"2873_CR301","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.ard.2025.05.214","volume":"84","author":"S Sheikh","year":"2025","unstructured":"Sheikh, S. et al. OP0202 ESET-SLE: CLINICAL TRIAL EVALUATING RESE-CEL (RESECABTAGENE AUTOLEUCEL), A FULLY HUMAN, AUTOLOGOUS 4-1BB ANTI-CD19 CAR T CELL THERAPY IN NON-RENAL SLE AND LUPUS NEPHRITIS. Ann. Rheum. Dis. 84, 168 (2025).","journal-title":"Ann. Rheum. Dis."},{"key":"2873_CR302","doi-asserted-by":"crossref","unstructured":"Abdalhadi, H. M., Chatham, W. W. & Alduraibi, F. K. CAR-T-cell therapy for systemic lupus erythematosus: a comprehensive overview. Int. J. Mol. Sci. 25, 10511 (2024).","DOI":"10.3390\/ijms251910511"},{"key":"2873_CR303","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11926-025-01207-7","volume":"27","author":"V Natoli","year":"2025","unstructured":"Natoli, V., Charras, A., Smith, E. M. & Hedrich, C. M. Juvenile-onset systemic lupus erythematosus: recent advances in pathogenesis and treatment. Curr. Rheumatol. Rep. 27, 42 (2025).","journal-title":"Curr. Rheumatol. Rep."},{"key":"2873_CR304","doi-asserted-by":"publisher","first-page":"eadt0795","DOI":"10.1126\/sciadv.adt0795","volume":"11","author":"S Oh","year":"2025","unstructured":"Oh, S., Khani-Habibabadi, F., O\u2019Connor, K. C. & Payne, A. S. Composition and function of AChR chimeric autoantibody receptor T cells for antigen-specific B cell depletion in myasthenia gravis. Sci. Adv. 11, eadt0795 (2025).","journal-title":"Sci. Adv."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02873-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02873-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T00:02:21Z","timestamp":1786406541000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02873-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,11]]},"references-count":304,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2873"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02873-4","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,11]]},"assertion":[{"value":"19 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"319"}}